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Previous studies have reported that adding protein (PRO) to a carbohydrate (CHO) 
solution can enhance endurance performance. This ergogenic effect may be a function of 
additional calories from supplemental protein/amino acids, but this thesis has not been directly 
examined. Additionally, L-alanine (ALA) is readily oxidized when provided during exercise; the 
impact that this has on metabolism and prolonged endurance performance is unknown. The 
purpose of this investigation was to assess performance and various cardiovascular and metabolic 
outcomes during prolonged cycling, to independently gauge the efficacy of whey PRO 
hydrolysate and ALA supplementation. Eight trained male and female cyclists (age: 22.3±2.0 




) performed 120 min of constant-load 
cycling (55% of peak power, 161.9±7.4 W) followed by a 30-km time trial (TT) under placebo 
(PLA), PRO, and ALA
 
conditions. TT performance was not different between treatments (PLA: 
57.6±1.6 min, ALA: 58.8±1.5 min, PRO: 58.8±1.8 min). VE, VO2, heart rate, rating of perceived 
exertion, blood glucose, blood lactate, and gastrointestinal distress were also similar across 
experimental conditions. Conversely, serum interleukin-6 (IL-6) levels following 120 min of 
cycling were elevated above rest with PLA (pre: 0.56±0.16, post: 3.14±0.84) and ALA (pre: 
1.14±0.46, post: 2.62±0.71) (p<0.05), but not with PRO intake (pre: 0.81±0.25, post: 1.55±0.32). 
The ingestion of PRO or ALA alone does not appear to enhance performance during prolonged 
cycling. Thus the ergogenic effects of CHO+PRO co-ingestion reported by others are likely not 







 For centuries man has attempted to manipulate nutrition in an effort to optimize 
performance. Dating back to 500-400 B.C. athletes and warriors were reported to ingest deer liver 
and lion heart prior to muscular work believing it to impart speed, bravery, and strength (3). Well 
into the 20
th
 century, ergogenic aid use was still guided more by superstition than science. In 
1925, Gordon et al. reported the first scientific evidence of improved physical condition with 
carbohydrate intake during a marathon race (61). Although improved performance from 
carbohydrate intake could be inferred from these results, it was not verified until much later, in 
the 1980’s, when Coyle and colleagues demonstrated that carbohydrate supplementation during 
prolonged cycling helps maintain blood glucose levels, carbohydrate oxidation rates, and 
consequently performance (33). Subsequent studies have substantiated the ergogenic effect of 
carbohydrate intake rates ranging from 30-60 grams/hour during prolonged endurance exercise 
(≥120 minutes) (32, 33). While it is clear that carbohydrate provision is beneficial during 
prolonged exercise, scientific query into other possible ergogenic aids to this type of exercise has 
continued. Specifically, researchers have examined the acute performance effects of various 
nitrogen-based supplements since the 1990’s without a clear consensus on the efficacy of such 
treatments (12). Therefore, the overarching purpose of this study is to investigate the effect of two 
separate nitrogen-based supplements (whey protein and l-alanine) on prolonged endurance 
performance. 
From a historical standpoint, our understanding of the role that endogenous protein and 
its constituent amino acids have as an energy provider during exercise shifted dramatically ~150 
yrs ago. Protein was believed to be the primary substrate used by contracting skeletal muscle until 
1866, when Fick and Wislicenus proved that non-nitrogenous fuels (carbohydrate and fat) yield 
the majority of energy (50, 86). Currently, protein is considered largely inconsequential as an 





ATP production. However, amino acids can be used to generate metabolites for intramuscular 
oxidative metabolism and serve as gluconeogenic pre-cursors in the liver to prevent 
hypoglycemia during prolonged exercise (38). In this manner, amino acids can supply 5-10 
percent of the total ATP utilized during exercise (19). Due to the relatively small contribution of 
amino acids to energy production and the abundance of endogenous stores, protein was virtually 
ignored until recently as a potential ergogenic aid to endurance exercise. 
 The performance value of protein intake during endurance exercise has gained interest 
over the past decade. This query has been addressed by exclusively examining the performance 
impact of adding small doses of protein (~5-20 g/hr) to standard carbohydrate treatments. 
Interestingly, initial studies demonstrated that protein enhances performance to a large extent (29-
36%) (69, 123). Subsequent research has been mixed, as protein co-ingestion with carbohydrate 
was beneficial in some studies (2, 47, 58, 69, 122–124), but not others (18, 41, 104, 116, 139, 
140). Stearns and colleagues recently reviewed the literature on this topic and determined that 
carbohydrate-protein supplements, when matched for carbohydrate content (treatments containing 
protein = more calories), generated a 10.5% improvement in performance over carbohydrate 
supplements (58). Some reports have also indicated that protein (6-10g/hr) combined with a low 
dose of carbohydrate (i.e. 25g/hr) is capable of maintaining or improving the performance 
efficacy of a higher total calorie carbohydrate (i.e. 50g/hr) beverage (47, 92, 93). This suggests 
that the effects of protein intake are more potent than carbohydrate. However, whether these 
studies would have detected a dose-response effect between the low and high carbohydrate 
beverage regardless of protein inclusion is questionable. In fact, many carbohydrate studies have 
been unable to detect a performance dose-response (i.e. more carbohydrate = proportionally 
larger gains in performance) (55, 57, 95, 96). Therefore, protein co-ingestion may not have 
played a role in maintaining performance in the aforementioned studies. 
The current literature possesses a number of important weaknesses, to which the current 





potential of protein intake during endurance exercise in some conditions (time to exhaustion 
protocols and iso-carbohydrate comparisons), the performance benefits of protein remain 
uncertain, particularly during time trial efforts. Most studies reporting a positive effect of protein 
utilized time to exhaustion (TTE) exercise protocols rather than time trial (TT) protocols.  
Although TTE protocols yield valuable insight, improvements in TTE performance do not always 
translate to proportional gains in TT performance. This weakens the external validity of TTE 
protocols (36, 70). Therefore, TT studies designed to examine the ergogenic effect of protein are 
needed to verify the prior positive TTE outcomes.  
Secondly, the independent effects of protein remain unknown as carbohydrate co-
ingestion likely influence the independent effects of protein due to competing mechanisms of 
each macronutrient (i.e. intestinal absorption and hepatic glucose production) (45, 72, 146). 
Finally, as highlighted above, all previous work on this topic has exclusively examined 
the effect of small doses of protein (~5-20 g/hr). These rates are low compared to the 
recommended rate of carbohydrate intake (30-60 g/hr), therefore possibly failing to optimize (and 
making it more difficult to discern) the potential ergogenic effect of protein. Therefore, the first 
primary aim of this study is to determine whether a moderate dose (45 g/hr) of whey protein 
delivered during prolonged cycling improves performance during a simulated, pre-loaded time 
trial compared to a placebo beverage. 
 The second primary aim of this study is related to the first, but will be addressed 
independently, as detailed below. Alanine, an individual amino acid present in whey protein (and 
many other protein sources), is the key amino acid extracted by the liver for gluconeogenesis, and 
as a partial result, is readily oxidized/decarboxylated during endurance exercise (45, 149). 
Supplementation of alanine during prolonged exercise has been shown to increase amino acid 
oxidation. Specifically, 51 of 73 grams of alanine supplementation were oxidized during three 
hours of cycling (82). Exogenous alanine accounted for 10% of the total energy expenditure 





only slightly lower than exogenous carbohydrate oxidation rates when carbohydrate was ingested 
at a similar rate (0.43 g/min) (111). Presumably, alanine served as a fuel through conversion to 
glucose in the liver and direct oxidation in the muscle by conversion to pyruvate (82). Whether 
this metabolic effect is capable of producing an ergogenic effect during prolonged exercise is 
unknown. The only study to investigate the performance outcome of alanine supplementation 
implemented a relatively short-duration protocol (60 minutes) (79). Alanine supplementation 
would more likely benefit performance during events that are metabolically demanding (i.e. 
prolonged exercise), a scenario that has yet to be examined. Therefore, the second primary aim of 
this study is to determine whether a moderate dose (45 g/hr) of alanine delivered during 
prolonged cycling improves performance during a simulated, pre-loaded time trial compared to a 
placebo beverage. Alanine intake not only warrants investigation for its ergogenic potential, but it 
may also provide some insight into the mode of action by which protein supplementation 
improves performance. Although this mechanism is unproven, the oxidation of amino acids 
provided by protein supplementation has been raised as a possibility (140). If alanine improves 
performance, it will likely result from increased exogenous energy provision (sparing of 
endogenous fuel stores), thereby suggesting that protein-induced performance gains can be 
partially ascribed to amino acid oxidation/gluconeogenesis. 
 On a more exploratory note, the impact of protein and alanine supplementation on plasma 
interleukin-6 (IL-6) will be investigated. Plasma IL-6 levels will be measured during cycling and 
will be used to provide insight into the impact of protein and alanine feedings on exercise 
metabolism. IL-6 is a myokine released from active skeletal muscle and is capable of impacting 
metabolism (6, 23, 56, 60, 77). The magnitude of the exercise-induced plasma IL-6 response is 
mediated by intensity and, more importantly, duration (24, 105, 106, 115, 132). Muscle glycogen 
depletion potentiates (75, 89, 130) and CHO supplementation attenuates (44, 99, 101, 128) the 
increase in plasma IL-6 observed with exercise. In this way, IL-6 serves as an energy sensor in 





AMPK activity (60, 77, 78, 89), which is likely how IL-6 increases free fatty acid oxidation and 
GLUT-4 translocation (and increasing skeletal muscle glucose uptake). Significant to the current 
study, IL-6 also enhances hepatic amino acid uptake, gluconeogenic gene mRNA abundance (e.g. 
PEPCK, G6P, and PGC-1α), and consequently gluconeogenesis (6, 52, 56, 88, 147). In this way, 
the exercise-induced increase in plasma IL-6 stimulates endogenous glucose production to 
maintain glucose homeostasis late in exercise. Interestingly, glutamine supplementation appears 
to augment the rise in plasma IL-6 during 120 minutes of cycling (67). Authors speculated that 
the increased plasma glutamine concentration, being a gluconeogenic pre-cursor, likely initiated a 
rise in plasma IL-6 to facilitate hepatic amino acid uptake. Regardless of the mechanism by which 
glutamine potentiates the exercise-induced plasma IL-6 response; it is capable of producing a 
favorable metabolic effect during prolonged exercise. Thus, the effect of both protein and alanine 
supplementation on plasma IL-6 will provide general information about how these nutrients 
influence the metabolic environment during prolonged exercise. Thus a secondary aim of this 
study is to determine whether protein or alanine supplementation during prolonged cycling 
influences plasma IL-6 following 120 minutes of cycling compared to a placebo beverage. 
The purpose of the current study is to gain a more complete understanding of the 
potential for both protein and alanine intake to improve prolonged endurance performance and to 





Aims and Hypotheses 
Primary Aim I: To determine whether protein supplementation during prolonged cycling 
improves performance on a simulated, pre-loaded time trial compared to a placebo beverage. 
Primary Hypothesis I: Protein supplementation will improve cycling time trial performance 
compared to a placebo beverage. 
Primary Aim II: To determine whether alanine supplementation during prolonged cycling 
improves performance on a simulated, pre-loaded time trial compared to a placebo beverage. 
Primary Hypothesis II: Alanine supplementation will improve cycling time trial performance 
compared to a placebo beverage. 
 
Secondary Aim: To determine whether protein or alanine supplementation during prolonged 
cycling influences plasma IL-6 following 120 minutes of cycling compared to a placebo 
beverage. 
Secondary Hypothesis: Both protein and alanine supplementation will elicit higher plasma IL-6 
levels following 120 minutes of cycling compared to a placebo beverage, with alanine 






 Several studies have demonstrated that carbohydrate-protein supplementation improves 
performance compared to an iso-carbohydrate beverage. However, a nearly equal number of 
studies have refuted this with null findings. Importantly, no studies have investigated the 
influence of a moderate dose of protein. Intake rates equivalent to those recommended for 
carbohydrate supplementation (30-60 g/hr) may be necessary to amplify/maximize the effect of 
protein. Nor has any study isolated the effect of protein on prolonged cycling performance by 
utilizing a protein-only beverage. Furthermore, ingested alanine appears to be oxidized at rates 
similar to supplemental carbohydrate (when ingested at like rates): thus indicating the potential 
for alanine supplementation to exhibit an ergogenic effect on prolonged cycling. However, the 
effect of alanine supplementation on prolonged cycling performance has yet to be examined. IL-6 
plays a significant role in metabolism during prolonged exercise. IL-6 increases gluconeogenesis 
(6, 52, 147), free fatty acid oxidation (23), and skeletal muscle glucose uptake (60). Also, 
glutamine supplementation has been found to augment the plasma IL-6 response to exercise (67). 
If alanine and/or protein supplementation are also capable of augmenting plasma IL-6 during 
prolonged exercise it can point to a favorable metabolic effect of these treatments. Therefore, this 
study will determine the performance outcome as well as the potential for an IL-6 mediated effect 





Review of the Literature 
Objectives 
 The objectives of this chapter are to provide an overview of: 1)  the representative 
literature on standard hydration and nutrition strategies for prolonged exercise, 2) the 
performance effect of a small dose of protein in a carbohydrate-based sports supplement, 3) the 
performance effect of amino acid consumption during exercise, 4) the physiological effect and 
proposed mechanisms for an amino acid based ergogenic effect, 5) alanine metabolism and the 
effect of supplementation, and 6) the factors that affect interleukin-6 and it’s metabolic impact. 
 
Water and Carbohydrate Supplementation 
 Prolonged exercise (≥120 minutes) is associated with marked physiological stress. For 
instance, endurance exercise necessitates a sweat response to avoid dangerous elevations in body 
temperature. However, sweat loss is capable of impairing performance if dehydration (loss of 
>2% body weight from fluids) is not avoided (125). Dehydration can impair performance by 
increasing heart rate and core temperature, and compromising stroke volume and cardiac output 
(7, 64). Fluid intake during prolonged exercise can help maintain plasma volume and 
consequently sweat rate, body temperature, stroke volume, heart rate, and cardiac output, thereby 
preserving performance capacity (7, 8, 64, 112). Thus, fluid replacement is prescribed at amounts 
necessary to avoid >2% loss of body weight from fluid while remaining at a tolerable rate to 
avoid gastrointestinal distress (125). In a previous position stand on the fluid replacement 
requirements during exercise, the American College of Sports Medicine recommended that fluid 
be ingested at a rate of ~600-1200 ml/hr during intense exercise lasting longer than one hour;  an 
individualized amount that should not exceed sweat rates (31). 
 Similarly, prolonged exercise creates a challenging metabolic environment. In resting 





intensities consequently require more ATP and carbohydrate oxidation becomes the predominate 
source of this energy (117). Therefore, to sustain high levels of exercise intensity it is necessary 
to maintain high rates of carbohydrate oxidation. However, endogenous carbohydrate supply 
(blood glucose, muscle glycogen, and liver glycogen) is inherently limited and depleted stores 
have been shown to impair exercise performance (73, 85). Carbohydrate supplementation during 
prolonged exercise provides it’s ergogenic effect by delivering substrate for exogenous 
carbohydrate oxidation; thereby preventing a drop in blood glucose concentrations (33, 51), 
sparing liver glycogen (71, 72), and maintaining high rates of carbohydrate oxidation late in 
exercise (32). Recommendations for carbohydrate intake during exercise range from 30 to 60 g/hr 
(114). Recently, however, a dose-response effect has been found with carbohydrate 
supplementation up to 60 g/hr (126). Therefore, intake towards the upper end of this traditional 







Table 2.1: Fluid Intake 
Study Subjects Exercise Treatment Outcome 
Pitts 1944 
(112) 
6 Males 240-360 min marching 
@ 3.5mph up a grade 
of 2.5% 
 No Water 
 
 
 Water (ad libitum) 
 
 Water (matched BW loss) 
 ↑ HR and Tre; ↓ sweat rate and mechanical 
efficiency; earlier exhaustion due to 
dehydration 
 ↑ Tre late in exercise, but finished feeling 
fairly fresh 
 Tre remained very low and felt capable of 








 Subjects permitted commercially 
available beverage ad libitum 
(1594 and 735ml) 
 Tre ↑ then plateaued. Late exercise ↑ (peak 
= 41.9°C & 39.6°C). 
 ↑ in Tre late in exercise was result of ↓ 
evaporative heat loss (caused by 2.7 and 
3.1% loss of BW) 
Barr 1991 
(7) 
5 Male and 3 
Female 
Cyclists 
360 min @ 55% 
VO2max w/ intermittent 
breaks for 
measurements 
 No Fluid 
 
 
 Water (Matched BW loss) 
 Saline (Water+25mmol/l NaCl) 
 Higher HR, Tre, plasma Na, and RPE. 
Terminated exercise ~90 min early w/ 
6.4% loss of BW. 





120 min @ 70% 
VO2max 
 
 No Fluid 
 Fluid (1.17 L/hr) 
From min 20 to 120: 
 15% ↓ SV; 7% ↓ CO; 10% ↑ HR 





50 min @ 80% 
VO2max; ~10 min TT 
 Fluid (1330ml) 
 
 PLA (200ml) 
 TT: 10.22min; HR 4 bpm ↓ and Tre 
0.33°C ↓ after 50 min 
 TT: 10.93min 





120 min @ 69% 
VO2max; TTE @ 90% 
VO2max 
 High Fluid (1.16 L/hr) 
 Low Fluid (0.58 L/hr) 
 No Fluid 
 TTE: 328 sec 
 TTE: 248 sec 
 TTE: 171 sec 
 High fluid ↑ performance compared to no 







Table 2.1: Fluid Intake (Continued) 





80km TT  LO (0 and 426 ml/hr) 
 HI [670 ml/hr (ad libitum); 865 
ml/hr; 1324 ml/hr] 
 TT: 129 min 
 TT: 125 min 
 Fluid below ad libitum impairs performance; 
above does not impart greater benefits 
HR = Heart Rate; Na = Sodium; RPE = Rating of Perceived Exertion; BW = Body Weight; SV = Stroke Volume; CO = Cardiac Output; TTE = 







Table 2.2: Carbohydrate Supplementation 
Study Subjects Exercise Treatment Outcome 
Coyle 1983 
(33) 
9 Male and 1 
Female 
Cyclists 
TTE @ 74% VO2max  PLA 
 CHO (~70g @ 20 min; 
~17.5g @ 60, 90, & 120 
min) 
 TTE: 134min 
 TTE: 157min; ↑ blood glucose concentrations 
Fielding 1985 
(51) 
9 Males 240 min cycling @ 
50% VO2max w/ 
intense intermittent 
intervals; TTE @ 
100% VO2max 
 PLA 
 CHO: 21.5g every 60min 
 CHO: 10.75g every 
30min 
 TTE: 81 sec; ↓ blood glucose 
 TTE: 111 sec; ↔ plasma glucose; ↑ rate of CHO 
oxidation 
 TTE: 121 sec; ↔ plasma glucose; ↑ rate of CHO 
oxidation 
 CHO every 30 min ↑ TTE compared to PLA 





TTE @ 71% VO2max  PLA 
 CHO (~134g @ 20 min; 
~27g every 20 min) 
 TTE: 181min; ↓ plasma glucose 
 TTE: 241min; ↔ plasma glucose; ↑ rate of CHO 
oxidation 
 Equal muscle glycogen utilization 
Jeukendrup 1999 
(72) 
6 Cyclists 120 min @ 50% 
VO2max 
 PLA 
 LoCHO (35.5g/hr) 
 HiCHO (177g/hr) 
 
 Partially suppressed HGP 
 Completely suppressed HGP 






120 min @ 77% 
VO2max; 20km TT 
 PLA 
 15g CHO/hr 
 30g CHO/hr 
 60g CHO/hr 
 TT: 36.4 min 
 TT: 35.2 min 
 TT: 35.0 min 
 TT: 34.7 min 
 Performance: 60g/hr > 30g/hr = 15g/hr > PLA 
 Associated with a small ↑ in CHO oxidation 
 30 and 60g/hr ↓ liver glucose production 








Carbohydrate and Protein Co-Ingestion – Performance 
 In contrast to carbohydrate and water supplementation, it was not until recently that 
researchers began testing the efficacy of adding a small amount of protein (5-20 g/hr) to a 
standard carbohydrate-based sports drink during prolonged exercise. Initial rationale for this 
research question was based on the notion that protein could potentiate the insulin response to 
carbohydrate supplementation during exercise, thereby exhausting a smaller amount of muscle 
glycogen. However, this theory has been disproven as supplemental protein does not modulate 
the insulin response to carbohydrate intake during prolonged exercise (69). Nonetheless, initial 
findings were positive, as the addition of protein appears to confer a large performance effect (29-
36% improvement) compared to an iso-carbohydrate beverage (69, 123). However, subsequent 
data have been equivocal with some supporting an ergogenic effect of protein co-ingestion (2, 47, 
58, 93, 122, 124), while others have indicated no improvement (18, 41, 104, 116, 139, 140). A 
2010 meta-analysis of these studies established a significant improvement in performance when 
supplements were matched for carbohydrate content, but not when matched for calories (129). 
Some studies have also found that protein added to a small dose of carbohydrate is capable of 
maintaining the ergogenic effect of a higher total calorie carbohydrate beverage (47, 92, 93). This 
suggests protein inclusion in a sports drink may be capable of providing an equal ergogenic effect 
to a carbohydrate-only beverage while reducing the amount of calories that an athlete must 
intake. Furthermore, the literature has recently expanded beyond typical endurance exercise to 
include soccer. Protein and carbohydrate co-ingestion improved high intensity running capacity 
following a simulated soccer game compared to a carbohydrate-only beverage (2), suggesting that 
protein may be capable of exerting an ergogenic effect during other forms of non-continuous high 
intensity exercise (i.e. basketball, field hockey, etc.). However, skepticism over recommending 
protein as an ergogenic aid persists, presumably due to methodological limitations in the current 
literature. For example, most studies reporting a positive effect utilized time to exhaustion 








athletes do not compete in events that require maintaining a fixed power output as long as 








Table 2.3: Carbohydrate and Protein Co-Ingestion – Performance 





180 min varied 
intensity cycling (45-
75% VO2 peak); TTE @ 
85% VO2peak 
 PLA 
 CHO (47g/hr) 
 CHO+PRO (47+12g/hr) 
 TTE: 12.6 min 
 TTE: 19.7 min 
 TTE: 26.9 min 





TTE @ 75% VO2peak  CHO (37.2g/hr) 
 CHO+PRO (37+9g/hr) 
 TTE: 82.3 min 
 TTE: 106.3 min 
 PRO ↑ ergogenic effect of iso-CHO beverage 




80 km Time Trial (TT)  PLA 
 CHO (60g/hr) 
 CHO+PRO (60+20g/hr) 
 TT: 141 min 
 TT: 135 min 
 TT: 135 min 
 With optimal dose of CHO (60g/hr), PRO had no 





TTE @ 70% VO2peak  CHO (60g/hr) 
 CHO+PRO (45+12g/hr) 
 TTE: 138 min 
 TTE: 141 min 




8 Male and 5 
Female 
Cyclists 
TTE @ 75%  CHO (40.9g/hr) 
 CHO+PRO (41+10g/hr) 
 Gel Supplements 
 TTE: 102.8 min 
 TTE: 116.6 min 
 PRO ↑ ergogenic effect of iso-CHO equally in 





120 min @ 5% below 
OBLA; Time to 
complete set amount 
of work (7kJ/kg) 
 PLA 
 CHO (60g/hr) 
 CHO+PRO (75+16g/hr) 
 TT: 39.7 min 
 TT: 37.1 min 
 TT: 38.8 min 
 CHO ↑ over PLA only; ↔ between CHO+PRO 
and either treatment 
 ↑ CHO and caloric content in CHO+PRO may 








Table 2.3: Carbohydrate and Protein Co-Ingestion – Performance (Continued) 





TTE @ 75% 
VO2peak 
 PLA 
 CHO (78g/hr)  
 CHO+CHO (97g/hr) 
 CHO+PRO (78+19g/hr) 
 TTE: 107.1 min 
 TTE: 117.5 min 
 TTE: 121.3 min 
 TTE: 126.2 min 
 CHO+CHO and CHO+PRO ↑ over PLA, with ↔ 
between CHO and any treatment 
 At least some of the additive ergogenic effect of 





60 km TT  CHO (60g/hr) 
 CHO+PRO (60+18g/hr) 
 TT: 135.0 min; Final 20km: 45.0 min 
 TT: 134.4 min; Final 20km: 44.3min 
 With optimal dose of CHO, PRO did not affect total 





120 min @ 55% 
Wmax; ~1 hr TT 
(~880kJ) 
 CHO (65g/hr) 
 CHO+PRO (65+19g/hr) 
 TT: 60:13 
 TT: 60:51 







60 min @ 60% 
VO2peak; TTE @ 
90% VO2peak 
 PLA 
 Sago (60g CHO) 
 Sago+Soy (53+15g PRO) 
 TTE: 4.09 min 
 TTE: 5.49 min 
 TTE: 7.53 min 





45 min variable 
intensity cycling; 6 
km TT 
 CHO (95g) 
 CHO+PRO (72+22g) 
 TT: 433 sec 
 TT: 438 sec (p=0.048) 
 Replacing some CHO with PRO resulted in 1% 








Table 2.3: Carbohydrate and Protein Co-Ingestion – Performance (Continued) 








150 min varied 
intensity cycling 
(55-75% VO2peak); 
TTE @ 80% VO2peak 
 PLA 
 CHO (45g/hr) 
 LCHO+PRO (23+6g/hr) 
 HCHO+PRO (34+9g/hr) 
 TTE: 14.7 min 
 TTE: 26.9 min 
 TTE: 28.9 min 
 TTE: 30.5 min 
 Each treatment delayed fatigue compared to PLA; ↔ 
between others 








180 min varied 
intensity cycling 
(45-70% VO2peak); 
TTE @ 74-85% 
VO2peak 
 CHO (50g dextrose/hr) 




 TTE: 26 min 
 TTE: 31 min (p=0.064) 
 TTE in cyclists @ or below VT: CHO-35.5 min; 
CHO+PRO-45.6 min (p=0.006) 
 Below VT PRO delayed fatigue even with 50% ↓ CHO 





180 min varied 
intensity cycling 
(54-70% VO2peak); 
TTE @ VT 
(~75.06% VO2peak) 
 CHO (50g dextrose/hr) 




 TTE: 42 min 
 TTE: 50 min 
 PRO co-ingestion delayed fatigue in women with 50% 
less CHO and 30% fewer calories 
 Ergogenic affect likely the result of PRO inclusion and 










designed to simulate 
soccer game with 15 
min half-time; RTF 
@ 80% VO2peak 
 PLA 
 CHO (70.8g) 
 CHO+PRO (49.6+21.2g) 
 Given prior to testing 
and during half-time 
 RTF: 11.0 min 
 RTF: 16.5 min 
 RTF: 23.0 min 
 CHO+PRO delayed fatigue compared to CHO and PLA 
 PRO can exert ergogenic benefit during intermittent 
activity 
PRO = Protein; CHO = Carbohydrate; GI = Gastrointestinal; VT = Ventilatory Threshold; RTF = Running To Fatigue; TTE = Time to Exhastion; 








Amino Acid Ingestion – Performance 
In addition to whole protein sources (i.e. soy and whey), the performance effect of 
various amino acids [branch-chain amino acids (BCAA), tyrosine, mixed amino acids, and 
alanine] has also been examined. Of these amino acids, BCAA supplementation has been the only 
type of amino acid to exert an ergogenic effect. BCAA intake before and during prolonged 
exercise can decrease perceived exertion and improve physical as well as mental performance in 
humans and animals (12, 13, 21, 22, 97). These effects are thought to be due to diminished central 
fatigue (100). However, a number of other studies have contradicted these results with null 
findings (11, 27, 63, 90, 135, 142, 148). Another amino acid potentially capable of effecting 
performance through reduced central fatigue is tyrosine. However, it has been largely ineffective 
for performance (28, 135, 136). This may have been due to major weaknesses in methods of these 
studies. Specifically, Struder et al. and Sutton et al. provided tyrosine early, but not late in 
exercise (135, 136). Thus, the plasma tyrosine concentration was possibly unchanged from the 
placebo trial late in exercise, which would fail to exert an ergogenic effect. Chinevere et al. 
utilized tyrosine supplementation throughout exercise, but the statistical power was too weak to 
draw conclusions about its ergogenic effect. Another individual amino acid, alanine, has been 
investigated as an ergogenic aid due to its ability to provide exogenous energy (82). However, the 
only study to investigate alanine supplementation subjected cyclists to an exercise protocol of 
insufficient duration (60 minutes) to stress endogenous fuel stores (79). Therefore, further 
research investigating the ergogenic effect of alanine supplementation throughout prolonged 
exercise is necessary before conclusions can be drawn. As is shown above, various amino acids 
have the potential to impart an ergogenic effect during prolonged exercise through multiple 









Table 2.4: Amino Acid Ingestion – Performance 









Marathon (<3:30 min)  PLA 
 BCAA (16g Total) 
 
Subjects were permitted any 
other drinks ad libitum. 
 Performance: BCAA ↑ performance for 
slower (3.05-3.30 hr) but not faster (<3.05 
hr) marathon runners 
 Mental performance was ↑ post-exercise 
with BCAA 
 BCAA ingestion ↑ plasma concentration of 






90 min Soccer Game  CHO (78g) 
 CHO+BCAA (78g + 9.75g) 
 




34 Rats Moderate intensity 




 BCAA  
Ingested before/during exercise 
 TTE: 191min 
 TTE: 208min 
 TTE: 179min 
 CHO delayed fatigue compared to BCAA 




TTE @ 70-75% Pmax  CHO (78g sucrose) 
 Tryptophan (3.9g+78g 
sucrose) 
 L-BCAA (7.8g+78g sucrose) 
 H-BCAA (23.4g+78g 
sucrose) 
 TTE: ↔ between any trial (~122 min) 
 Believed to ↑ brain tryptophan levels 7- to 
20-fold 






100 km TT  PLA 
 CHO (87.5g 
maltodextrin+87.5g glucose) 
 CHO+BCAA (CHO+18g 
BCAA) 
 TT: 159.8min 
 TT: 160.1min 
 
 TT: 157.2min 







exercise prior to trials. 
60 min @ ~70% VO2max; 
20 min TT 
 PLA 
 BCAA (6.7g) 
 TT: 250kJ 
 TT: 275kJ; ↑ cognitive performance; ↓ 
RPE and mental fatigue. 








Table 2.4: Amino Acid Ingestion – Performance (Continued) 
Study Subjects Exercise Treatment Outcome 
Calders 1997 
(22) 




Injected prior to exercise 
 TTE: 76min 
 TTE: 99min 
 BCAA extended time to exhaustion. 
Mittleman 1998 
(97) 
7 Males and 6 
Females 
Temp-34.4°C 
120 min rest 
TTE @ 40% VO2peak 
 PLA 
 BCAA (Males-15.8g; 
Females-9.4g) 
 TTE: 137min 
 TTE: 153min 
 BCAA supplementation delayed the onset 





TTE @ workload that 
corresponds to blood 
lactate level of 
2.0mmol/L 
 PLA 
 Paroxetine (20mg; 
serotonin re-uptake 
inhibitor) 
 BCAA (14g; 7g @ 60min) 
 L-Tyrosine (10g; 10g @ 
60min) 
 TTE: 157 min 
 TTE: 131 min; augmented brain 
serotonergic activity and fatigue 
 
 TTE: 152 min 
 TTE: 150 min 
Calders 1999 
(21) 







Injected prior to exercise 
 TTE: 118min 
 TTE: 179min 
 TTE: 158min 
 TTE: 171min 
 BCAA ↓ fatigue compared to PLA; ↔ 
compared to CHO 
 BCAA has no additional effect when 








Table 2.4: Amino Acid Ingestion – Performance (Continued) 
Study Subjects Exercise Treatment Outcome 
Chinevere 2002 
(28) 
9 Cyclists 90 min @ 70% VO2peak; 
TT (amount of work that 
would be completed in 30 
min @ 70% VO2peak) 
 PLA 
 CHO (51g/hr) 
 Tyrosine+CHO (3.65+51g/hr) 
 Tyrosine (3.65g/hr) 
 TT: 34.4 min 
 TT: 27.2 min 
 TT: 26.1 min 
 TT: 32.6 min 
 Statistical power for differences between 
CHO & Tyrosine+CHO (0.11) and PLA 




8 Males Glycogen depleted state 
Temp-30°C 
TTE @ 50% VO2peak 
 PLA 
 BCAA (6g/hr during 2 hr rest; 
7.2g/hr during exercise) 
 TTE: 103.9 min 
 TTE: 111.0 min 






Glycogen depleted and 
hypohydrated 
Temp-40°C 
60 min @ 50% VO2peak; 30 
min TT 
 CHO (70g) 
 CHO+BCAA (60g 
CHO+10g BCAA) 
 Mean power output: 79.5W 
 Mean power output: 91.7W 
 ↔ in performance 




20 Males 120 min (or until volitional 
exhaustion) treadmill w/ 
weighted backpack @ 70% 
VO2max; handgrip, pull-ups, 
and stair-stepping tests 
30 min prior to exercise:  
 PLA 
 L-Tyrosine (12.1g) 
 
 119.2 min 
 118.9 min 




9 Male and 1 
Female 
Cyclist 
45 min @ 75% VO2peak; 15 
min performance trial 
(amount of work completed 
in 15 min) 
 PLA 
 CHO (30g prior; 45g during) 
 ALA (30g prior; 45g during) 
 CHO+ALA (30+30g prior; 
45+45g during) 
 Work completed: 229 kJ 
 Work completed: 222kJ 
 Work completed: 219kJ 
 Work completed: 218kJ 








Table 2.4: Amino Acid Ingestion – Performance (Continued) 









 Amino Acid Pills (52.5g Total) 
Subjects were allowed food and 
drinks ad libitum. 
 Performance: 698 min 
 Performance: 624 min (p=0.033) 
 When adjusted for personal best time in 
previous 100km races, difference was no 
longer significant 
PLA = Placebo; CHO = Carbohydrate; PRO = Protein; ALA = Alanine; BCAA = Branched-Chain Amino Acids; TT = Time Trial; TTE = Time to 








Protein/Amino Acid Ingestion – Physiological Effect and Proposed Mechanisms 
Central Fatigue 
 Though a number of mechanisms have been proposed, a clear mechanistic explanation 
for how a small dose of protein can enhance endurance performance remains elusive. 
Traditionally, peripheral mechanisms (muscular fatigue) are credited with fatigue during 
endurance exercise, but central means have also been linked to fatigue during endurance 
performance (4). The most widely researched mechanism to date is the effect of amino acid 
provision on central nervous system fatigue. Brain concentration of tryptophan is a pre-cursor for 
serotonin, which has been linked to lethargy in humans (10, 48). Plasma free-tryptophan 
competes with other plasma neutral amino acids (i.e. tyrosine, alanine, phenylalanine, leucine, 
and valine) for transport across the blood-brain barrier (49, 107, 151). Therefore, the plasma free-
tryptophan/neutral amino acid ratio is the main determinate of brain serotonin levels. During 
prolonged exercise plasma free-tryptophan increases and plasma neutral amino acids decreases 
causing elevated brain tryptophan (10, 15). Therefore, neutral amino acid supplementation 
increases the concentration of plasma neutral amino acids and inhibits the uptake of plasma 
tryptophan by the brain (49, 63). This subsequently decreases brain serotonin synthesis, thus 
theoretically attenuating central fatigue. However, whether this actually attenuates central fatigue 
in practice is unknown. Tyrosine supplementation is thought to not only attenuate brain uptake of 
tryptophan, but also potentiate uptake of tyrosine and consequently increase synthesis of 
dopamine (26).  However, as stated previously, it has not been established that tyrosine increases 
endurance performance (28, 135, 136). However, some studies have found neutral amino acid 
supplementation (BCAA) to diminish perceived exertion, improve performance, and increase 
cognitive function during endurance exercise (11–13, 21, 22, 97), but others have shown no effect 
(27, 63, 90, 135, 142, 148). Due to equivocal results, firm conclusions about the effect of neutral 









Tricarboxylic Acid Cycle Intermediates 
 Another potential mechanistic explanation for the acute performance benefit of 
protein/amino acid supplementations is an increase in tricarboxylic acid cycle intermediate 
(TCAI) pool size. TCAI levels rapidly increase at the onset of exercise and then slowly decreases 
with exercise duration (59, 121). It was previously surmised that depletion of TCAI contributes to 
fatigue by impairing aerobic energy production (121), and that protein intake could maintain 
TCAI pool size and sustain aerobic energy provision (69). However, it now appears that TCAI 
pool size is inconsequential for oxidative metabolism (17). Moreover, researchers recently 
reported that protein co-ingestion with carbohydrate has no effect on TCAI pool size compared to 
carbohydrate supplementation alone during exercise (25). 
 
Fluid, Sodium, and Carbohydrate Delivery 
 Certain amino acids (arginine, glutamine, and alanine) have been found to increase 
intestinal absorption of sodium, fluid, and glucose in vitro (29, 146), all of which could favorably 
impact performance. Neutral amino acids are absorbed from the intestines at a comparable rate to 
that of carbohydrate (37) and co-transported with sodium across the intestines via glucose 
independent transporters (29). Due to increased sodium absorption with neutral amino acids, 
more fluid can be absorbed from the intestines via solvent drag (87). Therefore, amino acid 
supplementation is capable of improving performance through increased fluid replacement and, 
when carbohydrate is co-ingested, exogenous carbohydrate oxidation. Arginine (0.44g/hr), but 
not glutamine, co-ingestion with carbohydrate was reported to increase exogenous carbohydrate 
oxidation by 12% (118). However, milk protein concentrate co-ingestion (~0.41g arginine/hr) 
with carbohydrate did not increase exogenous carbohydrate oxidation (120). Therefore, it is 










Exogenous Amino Acid Oxidation 
 The final avenue by which protein/amino acid ingestion has been proposed to enhance 
performance is through exogenous energy provision, thereby slowing endogenous substrate 
utilization. Endogenous protein is typically considered a poor source of ATP, as it supplies only 
5-10% of the total energy cost of exercise. Nonetheless, amino acids are oxidized in skeletal 
muscle (Figure 2.1) and provide gluconeogenic pre-cursors to the liver late in exercise in an 
attempt to maintain blood glucose concentrations (143). Exogenous amino acids have been shown 
to be oxidized during exercise in this manner (30, 81, 82). Protein inclusion (18 g/hr) in a 
carbohydrate beverage results in a two-fold increase in amino acid oxidation during prolonged 
exercise (81). Furthermore, 50.6 g of the 73.7 g supplemented alanine was oxidized during three 
hours of cycling (82). This proposed mechanism has a considerable amount of evidence, as most 
studies reporting performance gains with protein co-ingestion have been compared to 
carbohydrate matched treatments rather than calorically-matched treatments, which points to an 
energy provision effect of protein/amino acid supplementation. However, most studies have 
utilized rates of protein/amino acid intake well below the rate of carbohydrate intake known to 
produce a clear metabolic effect (30-60 g/hr). Additional research with protein/amino acid intake 
rates equivalent to those recommended for carbohydrate are necessary to examine the maximum 








Table 2.5: Protein/Amino Acid Ingestion – Physiological Effect and Proposed Mechanisms 
Study Mechanism Exercise Treatment Outcome 
Fernstrom 1971 
(48) 
Central Fatigue  Normal physiological 
dose of tryptophan given 
to rats 
 Plasma and brain tryptophan ↑ 10 to 60 minutes 
after injection 
 Brain serotonin concentrations were ↑ 60 
minutes after injection 
 Tryptophan is rate limiting for serotonin 
synthesis in the brain 
Fernstrom 1972 
(49) 
Central Fatigue    ↑ plasma tryptophan leads to ↑ brain tryptophan 
and brain serotonin 
 Even when plasma tryptophan is ↑, brain 
serotonin does not ↑ when other plasma neutral 
amino acids are elevated 
 The ratio of tryptophan: neutral amino acid (i.e. 
alanine, tyrosine, phenylalanine, leucine, and 




Central Fatigue    Uptake of plasma tryptophan by the brain is 
concentration dependent 
 Some albumin bound-tryptophan is stripped 
from albumin during passage for uptake into the 
brain, but free-tryptophan is more easily 
transported 
 Amino acid competition for carrier sites across 
the blood brain barrier is the most important 










Table 2.5: Protein/Amino Acid Ingestion – Physiological Effect and Proposed Mechanisms (Continued) 
Study Mechanism Exercise Treatment Outcome 
Pardridge 1977 
(107) 
Central Fatigue    Neutral amino acids compete for a single transport 
site across the blood-brain barrier with tryptophan 
 The tryptophan: neutral amino acid ratio regulates 
the brain uptake of these amino acids 
Asmussen 1979 
(4) 
Central Fatigue    Two forms of fatigue exist; central and peripheral 
fatigue 




Central Fatigue 1986 Stockholm 
Marathon or 90 min 
Army Training 
  Plasma concentration of BCAA ↓ during both 
types of exercise 
 Plasma concentration of free tryptophan was ↑ 
2.4-fold 
 ↑ in free tryptophan: BCAA ratio should lead to 
an ↑ in the rate of tryptophan transport across the 
blood brain-barrier and an ↑ in synthesis of 
serotonin 
 Serotonin has been linked to lethargy in humans 
 ↑ concentrations of serotonin in specific areas of 




Central Fatigue Treadmill running to 
fatigue in rats 
  Running to fatigue ↑ ratio of plasma free 
tryptophan: plasma neutral amino acids and 
subsequently brain tryptophan (↑ 36%) 
 Brain serotonin was ↑ at fatigue and may play a 








Table 2.5: Protein/Amino Acid Ingestion – Physiological Effect and Proposed Mechanisms (Continued) 
Study Mechanism Exercise Treatment Outcome 
Sahlin 1990 
(121) 
TCAI Cycled to fatigue @ 75% 
VO2peak 
  TCAI ↑ initially during exercise and then 
continually ↓ until fatigue 
 Aerobic energy production may be 
impaired by depleted TCAI levels 
Gibala 2002 
(59) 
TCAI 90 min leg kicking @ 70% 
of max one-legged 
capacity. 
Repeatedly measured TCAI  TCAI ↑ rapidly at the beginning of 
exercise before slowly ↓ to near resting 
levels 




TCAI 180 min varied intensity 
cycling (45-75% VO2 
peak);TTE @ 85% VO2peak 
 PLA 
 CHO (47g/hr) 
 CHO+PRO (47+12g/hr) 
 PRO ergogenic effect proposed as being 
due to ↑ supply of TCAI 
Cermak 2009 
(25) 
TCAI 90 min cycling @ 69% 
VO2peak 
 CHO (60g/hr) 
 CHO+PRO (60+20g/hr) 
 TCAI pool expansion was similar between 
trials 






Rest Humans Jejunum Perfused w/: 
 PLA 
 different concentrations of 
Glutamine 
 Saturation level of glutamine intestinal 
transport was similar to those previously 





Rest Rat Jejunum Perfused w/: 
 PLA 
 different concentrations of 
Arginine 
 1 to 20 mmol/L of Arginine ↑ intestinal 








Table 2.5: Protein/Amino Acid Ingestion – Physiological Effect and Proposed Mechanisms (Continued) 





Rest Humans Jejunum Perfused w/ 
 Glutamine 
 Glutamine & Glucose 
 Alanine & Glucose 
 Glucose 
 PLA 
 Glutamine and alanine ↑ sodium and fluid 
absorption in the human jejunum 
 Neutral amino acids are co-transported with 
sodium in the intestine that is independent 





150 min @ 50% Wmax  CHO+Glutamine (48+4g/hr) 
 CHO+Arginine (48+0.44g/hr) 
 CHO (48g/hr) 
 PLA 
 ↔ exogenous CHO oxidation; slight ↑ in GI 
discomfort 
 ↑ exogenous CHO oxidation (12%); ↓ O2 
consumption (2.6%); ↓ the lactate 






150 min @ 50% Wmax  CHO+PRO (48+12g/hr) 
 CHO (48g/hr) 
 PLA 
 ↔ exogenous CHO oxidation, gut comfort, 
or perceived exertion; ↑ endogenous CHO 





Marathon Run  CHO (81g) 
 CHO+PRO (81g+32g) 







180 min cycling @ 
53% VO2peak 
 73.7g alanine Before and 
During Exercise 
 50.6g of exogenous alanine was oxidized 
(68.7% of load).  
 Exogenous alanine accounted for 10% of 






150 min cycling; 60 
min running; 150 min 
cycling @ 50% VO2max 
 CHO (50g/hr) 
 CHO+PRO (50+18g/hr) 
 








Table 2.5: Protein/Amino Acid Ingestion – Physiological Effect and Proposed Mechanisms (Continued) 





TTE @ 75% VO2peak  PLA 
 CHO (78g/hr) 
 CHO+CHO (97g/hr) 
 CHO+PRO (78+19g/hr) 
 TTE: The isocaloric treatments (CHO+CHO 
and CHO+PRO) were significantly better than 
PLA while CHO was not different 
 At least some of the additive effect of PRO 
co-ingestion on performance is caused by ↑ 
calories 
PLA = Placebo; CHO = Carbohydrate; PRO = Protein; BCAA = Branched-Chain Amino Acids; TT = Time Trial; TTE = Time to Exhaustion; 












Modified from Wagenmakers, A. Muscle amino acid metabolism at rest and during exercise: role 

















Alanine Metabolism and Supplementation 
 Alanine is an amino acid that is readily oxidized/decarboxylated during exercise (149). 
Moreover, alanine is the principle amino acid extracted by the liver for gluconeogenesis (45). The 
glucose-alanine cycle (Figure 2.2) is a concept that outlines the production of alanine in the 
muscle and its subsequent conversion to glucose in the liver (46). As liver glycogen levels decline 
gluconeogenesis contributes more to hepatic glucose production. Consequently, liver uptake of 
alanine increases as a function of exercise duration; gluconeogenic pre-cursor uptake increases 2 
to 10-fold following four hours of cycling (1). Thus, alanine significantly contributes to the 
maintenance of blood glucose levels late in exercise. The important role that alanine has on 
metabolism has raised interest in the metabolic effect that alanine supplementation has during 
prolonged exercise. As mentioned previously, when supplemented during three hours of cycling, 
50.6 g of the 73.7 g of exogenous alanine were oxidized. The peak exogenous alanine oxidation 
rate (0.35g/min) was only slightly lower than those previously reported when carbohydrate was 
ingested at a similar rate (0.43g/min). Exogenous alanine contributed 10% of the total energy cost 
of exercise while endogenous protein contributed another 5%. Therefore, alanine supplementation 
at a higher rate (30-60 g/hr) is potentially capable of providing substrate to sustain aerobic energy 
production late in exercise. Currently, only one study has investigated the effect of alanine 
supplementation on endurance performance. Supplementation produced an ostensibly favorable 
metabolic effect, but the exercise test was of insufficient duration to challenge endogenous 








Table 2.6: Alanine Metabolism and Supplementation 




weight and 7 
obese adults 
Rest Overnight fast and 4 to 6 
weeks of total starvation 
 ALA is the principal amino acid precursor extracted 
by the liver for gluconeogenesis 
 ALA concentration is rate-limiting for 
gluconeogenesis 
 With prolonged starvation and subsequent ↓in plasma 




Dogs Rest Low dose of ALA, high 
dose of ALA; 
hyperglycemic w/ high 
dose of ALA 
 When fasted, ALA caused ↑ in plasma glucagon; very 
slight ↑ in insulin 
 When exogenous glucose is available ↔ in glucagon 
 Glucagon mediates gluconeogenesis—ALA causes an 
↑ in gluconeogenesis 
Ahlborg 1974 
(1) 
6 Males Studied at rest and 
during 240 min of 
cycling at ~30% 
VO2peak 
12-14 hour overnight 
fast 
 Leg output of ALA ↑ w/ exercise duration 
 Splanchnic uptake of gluconeogenic precursors ↑ 2 to 
10-fold after exercise (45% of hepatic glucose output) 
 As liver glycogen stores are ↓ gluconeogenesis 
contributes more to energy production 
 Blood glucose levels ↓ due to hepatic glucose output 






Rest, easy running 
(2hours), and hard 
running (2 hours) 
Glucose, alanine, and 
leucine tracer injections 
to measure oxidation 
rates. 
 Oxidative decarboxylation of amino acids (ALA and 
Leucine) ↑ during exercise 
 ALA is a readily oxidizable substrate during exercise 
 Plasma, muscle, and liver concentrations of ALA ↑ 








Table 2.6: Alanine Metabolism and Supplementation (Continued) 
Study Subjects Activity Treatment Outcome 
Williams 1998 
(150) 
6 Males 180 min treadmill 
exercise @ 45% 
VO2max 
Tracers used to quantify 
alanine and glutamine 
rates of appearance and 
kinetics. 
 ALA rate of appearance increased during exercise, 
but glutamine did not. 
 Amino-N delivery from muscle to liver increased 
during exercise. 






180 min Cycling @ 
53% VO2peak 
73.7g ALA Before and 
During Exercise 
 50.6g of exogenous ALA was oxidized (68.7% of 
load).  
 Exogenous ALA accounted for 10% of energy yield 
along with 5% from endogenous PRO. 
Klein 2009 
(79) 
9 Male and 
1 Female 
Cyclist 
45 min @ 75% 
VO2peak; 15 min 
performance trial 
(amount of work 
completed in 15 min) 
 PLA 
 CHO (30g prior; 45g 
during) 
 ALA (30g prior; 45g 
during) 
 CHO+ALA (30+30g 
prior; 45+45g during) 
 Work Completed: 229 kJ 
 Work Completed: 222kJ 
 
 Work Completed: 219kJ 
 
 Work Completed: 218kJ 
 ↔ Performance by treatment  
 Too short for metabolic effect 
 ALA ↑ plasma concentrations of gluconeogenic 
amino acids, but didn’t affect BCAA 
 Promoted metabolic profile favorable for 
performance 







Figure 2.2: Alanine-Glucose Cycle 
  
Modified from: Wagenmakers, A. Muscle amino acid metabolism at rest and during exercise: role in human physiology and metabolism. Exerc 










 Interleukin-6 (IL-6) is a myokine that plays a significant role in metabolism during 
prolonged exercise. The prevailing thought is that IL-6 is released from skeletal muscle as an 
energy sensor (109). Therefore, as exercise duration and/or intensity increases skeletal muscle 
releases additional IL-6 resulting in increased plasma IL-6 (54). Muscle glycogen content plays a 
large role in the increase in plasma IL-6. When exercise is initiated with low muscle glycogen the 
exercise-induced IL-6 response is much more prominent (75, 89, 130). Conversely, carbohydrate 
supplementation minimized the plasma IL-6 response. Therefore, the presence of carbohydrate in 
skeletal muscle (endogenous or exogenous) inhibits the release of IL-6 and attenuates the plasma 
IL-6 concentration (44, 99, 101, 128). 
 IL-6 impacts metabolism through a number of mechanisms. IL-6 increases AMPK 
activity by increasing the concentration of cAMP and, secondarily, the AMP-ATP ratio (77). This 
increase in AMPK activity potentiates free fatty acid oxidation and GLUT-4 translocation, which 
results in skeletal muscle glucose uptake (23). IL-6 also increases hepatic glucose production, by 
elevating gluconeogenic gene mRNA (PEPCK, G6P, and PGC-1α) as well as gluconeogenic pre-
cursor uptake (6, 52, 56, 147). Interestingly, glutamine supplementation, an individual amino 
acid, augments plasma IL-6 during prolonged exercise (67). Researchers speculated that the 
increased plasma glutamine concentration signaled for an increase in plasma IL-6 to facilitate 
hepatic amino acid uptake (67). Regardless of how glutamine supplementation increases plasma 
IL-6, it appears capable of producing a favorable metabolic effect during prolonged exercise. 
Thus, the effect of protein/amino acid supplementation on the exercise-induced plasma IL-6 








Table 2.7: Interleukin-6 





Rest—tested 30, 60, 90, 
120, and 180 min after 
injection 
Injected recombinant 
human IL-6 (rhIL-6) 
 IL-6 ↑ plasma corticosterone by central action on the 
hypothalamus-pituitary-adrenal cortex 
 IL-6 ↑ plasma glucagon and glucose. 
 Hepatic glycogen was ↓ compared to control 
 IL-6 altered the hormonal and CHO profile either by 




Adult Rats Rest Injection of 0.5mg/kg 
of dexamethasone and a 
varying concentration 
of IL-6 (10, 50, or 150 
μg/kg) 
 Amino acid transport in liver was analyzed 
 IL-6 and glucocorticoids were found to work together 
to ↑ hepatic amino acid uptake 
 A dose-response effect was seen with IL-6 on hepatic 







 IL-6 and TNF-α in 
combination with 
dexamethasone was 
added to hepatocyte in 
culture. 
 IL-6 and TNF-α exerted stimulatory effect on amino 
acid transport 







1991 and 1993 Brussels 
Marathons (avg time: 
3:45 and 3:42) 
  Post-marathon plasma IL-6 ↑ 45-fold 
Rohde 1997 
(115) 
6 Males 60 min of one-legged 
eccentric leg extension 




during, and after 
exercise (22.6g) 
 BCAA ↓ release of amino acids from muscle—↓ net 
muscle degradation 
 Plasma IL-6 ↑ after prolonged eccentric exercise 







Table 2.7: Interleukin-6 (Continued) 




9 Males 30 min cycling @ 
65% VO2max 
 Concentric 
 Eccentric (braking w/ 
reversed revolutions) 
 Plasma IL-6 ↑ 2 hours after eccentric cycling, but 
not concentric 






150 min running @ 
75-80% of VO2max 
 PLA 
 CHO (60g/hr) 
 Plasma IL-6 ↑ 753% post-run 
 Plasma IL-6 ↑ 441% post-run 






150 min of running or 
cycling @ 75% 
VO2max 
 PLA 
 CHO (60g/hr) 
 
 ↑ plasma glucose and insulin; ↓ cortisol and 
growth hormone; ↓ plasma IL-6 
  ↓ plasma IL-6 from cycling compared to running 
 CHO thought to reduce physiological stress 
Ostrowski 1998 
(106) 
16 Males Copenhagen 
Marathon (median 
time: 3:17:03) 
Allowed CHO and fluid 
ad libitum. 
 Plasma IL-6 ↑ ~63-fold immediately post-exercise 
 IL-6 mRNA ↑ in muscle post-exercise 
 IL-6 is locally produced in skeletal muscle 
Ostrowski 1999 
(105) 
10 Males Copenhagen 
Marathon (median 
time: 3:26) 
Allowed CHO and fluid 
ad libitum. 
 Plasma IL-6 ↑ ~128-fold immediately post-
exercise 
 Plasma IL-6 was more pronounced immediately 







120 min of cycling @ 
70% VO2peak 
 PLA 
 CHO (35g before; 
~60g/hr during) 
 Plasma IL-6 ↑ 2-fold post-exercise 
 Plasma IL-6 ↑ 2-fold post-exercise 









Table 2.7: Interleukin-6 (Continued) 
Study Subjects Activity Treatment Outcome 
Steensberg 2000 
(132) 
6 Males 5 hours of one-legged 
knee extensor exercise 
@ 40% Wmax 
  Plasma IL-6 ↑ 19-fold from rest 
 Net IL-6 release from muscle was 17-fold ↑ than the 
elevation in arterial IL-6 
 Net IL-6 release from muscle during one minute was 
half the total plasma content 
 Very high turnover of IL-6 during exercise 
 IL-6 is suggested to contribute to glucose 
homeostasis during prolonged exercise 
 Source of ↑ plasma IL-6 during prolonged exercise 






120 min of rowing 
(~57% VO2max) 
 PLA 
 CHO (55g pre-
exercise; 73g/hr 
during exercise) 
 Plasma IL-6 was ↔ by exercise and/or CHO 
Steensberg 2001 
(130) 
7 Males 4-5 hours (until 
exhaustion) of two-
legged knee extensor 
exercise @ 40% Wmax 
 Normal muscle 
glycogen leg 
 Low Muscle glycogen 
leg 
 Intramuscular IL-6 mRNA ↑; released IL-6 after 2 
hours of exercise 
 Augmented intramuscular IL-6 mRNA ↑; released 
IL-6 after 1 hour of exercise 
 Plasma IL-6 ↑ 36-fold 
 Glycogen availability alters IL-6 production and 
release in contracting muscle 
Keller 2001 
(75) 
6 Males 180 min of two-
legged knee extensor 
exercise @ 50-60% 
Wmax 
 Normal muscle 
glycogen 
 Low (60% of normal) 
muscle glycogen 
 ↑ plasma IL-6, IL-6 gene transcription and mRNA 
content from rest 
 ↑ plasma IL-6 earlier and higher; much higher IL-6 







Table 2.7: Interleukin-6 (Continued) 





2 trials of 60 min of 
cycling @ lactate 
threshold and 2 trials of 
60 min of running @ 
lactate threshold 
 PLA 
 CHO (64g) 
 Exercise resulted in a 21-fold ↑ in IL-6 mRNA 
expression regardless of mode or treatment 
 Mode of exercise did not affect ↑in plasma IL-6, but 




and 8 Control 
Subjects 




 IL-6 infusion caused ↑ in net glycerol release from 
subcutaneous adipose tissue while fatty acid release 
was unchanged 
 IL-6 caused vasodilation in the splanchnic region 
and uptake of fatty acids and the gluconeogenic 
precursors, glycerol and lactate 
 Splanchnic glucose and triacylglycerol output was 
↔ 




6 Males 180 min of two-legged 
knee extensor exercise 
@ 55% Wmax 
  IL-6 mRNA ↑ ~100-fold following exercise 
 IL-6 ↑ in arterial plasma throughout exercise 
 Net IL-6 release from the contracting limb was ↑ 




6 Males/group Rest 3 hours of: 
 high dose of rhIL-6 
 low dose of rhIL-6 
 PLA 
 ↔ endogenous glucose production, whole-body 
glucose disposal, and leg-glucose uptake 
 Expected ↑ in glucose uptake by skeletal muscle 







Table 2.7: Interleukin-6 (Continued) 






min cycling @ 60% 
VO2max 




 In muscle, IL-6 mRNA ↑ and peaked at the end of 
exercise 
 In adipose tissue, IL-6 mRNA ↑ 1.5 hours post-
exercise 
 rhIL-6 infusion resulted in ↑ IL-6 mRNA levels in 
the muscle 




7 Males 120 min semi-recumbent 
cycling @ 65% VO2max 
 PLA 
 CHO (64g/hr) 
 
 Decreased plasma IL-6 response; less net leg IL-6 
release 
 Intramuscular glycogen and IL-6 mRNA were ↔ 
between treatments 
 IL-6 release from muscle may be regulated by 
substrate availability while IL-6 mRNA is 





180 min treadmill 
running @ 70% VO2max 
 PLA 
 
 CHO (60g/hr) 
 875% ↑ plasma IL-6; 35.2-fold ↑ gene expression 
of IL-6 mRNA 
 507% ↑ plasma IL-6; 15.9-fold ↑ gene expression 
of IL-6 mRNA 





60 min cycling @ 70% 
VO2peak 
 Glycogen Depleted 
 
 
 Glycogen Loaded 
 IL-6 release from leg seen after 10 min; @ rest α1-
AMPK and α2-AMPK activities were ↑; post-
exercise α2-AMPK activity was ↑ 
 No IL-6 release from leg or α1-AMPK and α2-
AMPK activity 
 Plasma IL-6 ↑ similarly in both trials 







Table 2.7: Interleukin-6 (Continued) 







20 min cycling @ 
65% Wmax followed 
by a TT lasting ~43 
min 
Timing: 75g CHO @ 15 or 75 
min pre- 
Amount: 45 min pre- PLA; 25g 
CHO; 200g CHO 
 Exercise-induced ↑in plasma IL-6 was equal in 





120 min cycling @ 
75% VO2max 
 PLA (7g CHO) 
 Glutamine (7g) 
 PRO+Glutamine (27.4+2.5g 
PRO bound Glutamine+15g 
sucrose) 
 Plasma IL-6 response: 11-fold ↑ 
 Plasma IL-6 response: 18-fold ↑ 
 Plasma IL-6 response: 14-fold ↑ 
 Glutamine and PRO+Glutamine maintained the 
plasma glutamine concentration while the PLA 
had ↓ plasma glutamine 
 Glutamine uptake by the muscle possibly allowed 
for a ↑ IL-6 production 
 ↑ glutamine concentration may cause an ↑ 
demand for IL-6 release from muscle for IL-6 






150 min cycling @ 
65% VO2max 
 PLA 
 LCHO (32g prior, 38.4g/hr) 
 HCHO (64g prior; 76.8g/hr) 
 
 Both CHO supplements attenuated the ↑ in 
plasma IL-6 






and fixed speed test 
 Control 
 IL-6 deficient 
 IL-6 deficient mice had ↓ endurance and energy 
expenditure during exercise 




6 Males 120 min cycling  HI (70% VO2peak) 
 LO (40% VO2peak) 
 LO+IL-6 (40% VO2peak + 
rhIL-6 intended to mimic 
plasma IL-6 concentration of 
HI) 
 Rate of appearance and disposal of glucose was ↑ 
in HI and LO+IL-6 compared to LO 
 IL-6 contributes to the exercise-induced ↑ in 








Table 2.7: Interleukin-6 (Continued) 
Study Subjects Activity Treatment Outcome 
Kelly 2004 
(78) 
Mice 60 min swimming  Control 
 IL-6 knockout 
 Incubation with IL-6 ↑ phosphorylation of AMPK 
 In IL-6 knockout mice P-AMPK and P-ACC was 
↓ in muscle and adipose at rest and in response to 
exercise. 
 IL-6 can activate AMPK and partially contributes 
to the ↑ in AMPK activity in response to exercise. 
Fischer 2004 
(53) 
7 Males 180 min of two-
legged knee extensor 
exercise @ 50% 
Wmax /leg (same 
relative workload) 
Pre and Post 10 wks of one-
legged knee extensor 
training (60 min @ 75% 
Wmax 5x/wk) 
 Resting muscle glycogen content ↑ ~74% post-
training. However, glycogen content ↓ to same 
extent during exercise. 
 IL-6 mRNA ↑ 76-fold after exercise pre-training 
and only 8-fold post-training 





150 min cycling @ 
60% Wmax 
 PLA 
 CHO (74g/hr) 
 The exercise-induced plasma IL-6 ↑ was 
attenuated with CHO 
 Muscle IL-6 mRNA ↑ in both trials with no 
difference between treatments 
 Muscle glycogen content ↓ 68% during exercise 
with both treatments 
Keller 2005 
(74) 
7 Males 180 min of two-
legged knee extensor 
exercise @ 50% 
Wmax /leg (same 
relative workload) 
Pre and Post 10 wks of one-
legged knee extensor 
training (60 min @ 75% 
Wmax 5x/wk) 
 low glycogen leg 
 normal glycogen leg 
 Training ↑ basal IL-6 receptor mRNA 
 Training ↑ skeletal muscle sensitivity to IL-6 
 Exercise-induced ↑ in IL-6 receptor mRNA is 







Table 2.7: Interleukin-6 (Continued) 






euglycemic clamp and 
rhIL-6 infusion 
 IL-6 treatment of L6 
myotube 
 IL-6 increased glucose disposal without affecting the 
complete suppression of endogenous glucose 
production. 
 IL-6 treatment of myotube increased fatty acid 
oxidation, basal and insulin-stimulated glucose uptake, 
and translocation of GLUT4 to the plasma membrane. 
 IL-6 increased AMPK. 
 Effects of IL-6 on glucose and fatty acid metabolism 
likely mediated by AMPK. 
Glund 2007 
(60) 
22 Male Muscle 
Biopsies 
 Incubated w/ or w/out IL-
6. 
 IL-6 increased glucose transport 1.3-fold. 
 IL-6 increased glucose incorporation into glycogen 
(1.5-fold) and glucose oxidation (1.3-fold). 
 IL-6 increased phosphorylation of STAT3 and AMPK 




Rats Treadmill run to 
exhaustion 
 Control 
 Calcineurin inhibition 
 Exercise ↑ plasma IL-6 levels, IL-6 mRNA, and p38 
MAPK phosphorylation. 
 Calcineurin inhibition blunted the plasma IL-6 and 
gene transcription. 
 P38 MAPK and calcineurin activity are two signaling 








Table 2.7: Interleukin-6 (Continued) 
Study Subjects Activity Treatment Outcome 
Banzet 2009 
(6) 
Rats Treadmill run to 




















 Exercise—plasma glucose, muscle glycogen, and 
hepatic glycogen ↓ post-exercise. Hepatic glycogen 
was 5% of resting value. 
 Exercise—gluconeogenic gene mRNA levels (PEPCK, 
G6P, & PGC-1α) were ↑ 
 This suggests a key role of gluconeogenesis in hepatic 
glucose production which was associated with active 
IL-6 signaling in the liver 
 rhIL-6 ↑ IL-6 responsive gene mRNA in a dose-
dependent manner 
 During metabolically demanding exercise muscle 
derived IL-6 could help ↑ hepatic glucose production 




Rats  Rat EDL muscle 
incubated w/ IL-6 
 IL-6 activated AMPK in muscle by increasing the 
concentration of cAMP and, secondarily, the AMP-
ATP ratio. 
 This activation resulted in more sustained increase in 
PGC-1α and UCP3. 







Table 2.7: Interleukin-6 (Continued) 






60 min treadmill run 
Rat hepatoma cells w/ 
or w/out IL-6 
 
 IL-6 deficient 
 control 
 IL-6 stimulation of rat hepatoma cells ↑ glucose 
production 
 Injection of IL-6 slightly ↑ PEPCK 
 Normal mice had ↑ plasma IL-6, however plasma 
glucose, and hepatic G6P and PGC-1α were ↔ 
from IL-6 deficient mice 
 IL-6 doesn’t appear to be essential for ↑ glucose 




Mice 60 min swimming  IL-6 deficient 
 control 
 Post-exercise CXCL-1 ↑ in plasma, muscle, and 
liver. 
 ↑ plasma IL-6 and muscle IL-6 mRNA preceded 
the ↑ in CXCL-1. 
 The liver CXCL-1 mRNA was completely 
blunted in IL-6 deficient mice. 
 Liver CXCL-1 expression is regulated by muscle 
derived IL-6. 

















 Currently, standard practice during prolonged exercise is to ingest fluid at high enough 
rates to avoid >2% loss of body weight (resulting from fluid loss) while avoiding gastrointestinal 
distress (125). This rate of fluid replacement is commonly prescribed as 600-1200 ml/hr (31). 
Also, standard practice during prolonged exercise is to supplement carbohydrate at 30-60 g/hr 
(114). This practice improves performance by preventing hypoglycemia, sparing liver glycogen, 
and maintaining high carbohydrate oxidation rates late in exercise (32). Recently, protein and 
amino acid supplementation have garnered attention for their potential to enhance performance. 
Whether protein/amino acid was co-ingested with carbohydrate or individually, results have been 
equivocal with some authors reporting benefits (12, 69, 97, 123) and others finding no effect (18, 
27, 41, 90). One glaring deficit in the current literature on the ergogenic effect of protein/amino 
acid during prolonged exercise is the lack of a definitive mechanism by which protein improves 
performance. The combination of this deficiency and the equivocal performance findings has 
fueled debate about the legitimacy of protein/amino acid intake as an acute ergogenic strategy. 
 Numerous physiological mechanisms have been proposed to explain the amino acid 
mediated effect on performance. The most promising mechanism based on the current literature is 
increased energy provision from exogenous amino acids. Specifically, studies investigating 
protein co-ingestion with carbohydrate that have found positive results were compared to 
carbohydrate-matched treatments, not calorie-matched treatments (129). When the caloric 
differences between carbohydrate and carbohydrate-protein treatments were eliminated, 
performance gains have typically disappeared as well. Thus, it’s likely that the ergogenic effect 
found in these studies is at least partially derived from the additional energy provision of 
exogenous amino acids (140). Furthermore, an individual amino acid, alanine, can serve as a 
significant exogenous fuel source when supplemented during prolonged exercise (82). However, 
neither protein nor alanine has been supplemented at rates high enough to optimize a metabolic 








equivalent to those recommended for carbohydrate supplementation (30-60g/hr) are required to 
fully elucidate whether these supplements have an ergogenic value during prolonged exercise. 
 As exercise duration increases and muscle glycogen stores are utilized, IL-6 serves as an 
energy sensor and is released from working skeletal muscle (109). Carbohydrate supplementation 
attenuates this response (99). IL-6 plays a significant role in metabolism during prolonged 
exercise. Plasma IL-6 increases gluconeogenesis (6, 52, 147), free fatty acid oxidation (23), and 
skeletal muscle glucose uptake (60). In this way, IL-6 is capable of producing a favorable effect 
on metabolism during prolonged exercise. Also, glutamine supplementation has been found to 
augment the plasma IL-6 response to exercise (67). If alanine and/or protein supplementation are 
also capable of augmenting plasma IL-6 during prolonged exercise it can point to a favorable 
metabolic effect of these treatments. 
 The current project was designed to investigate the efficacy of large doses of both protein 
and alanine intake on prolonged cycling performance. Furthermore, the exercise-induced plasma 







8 endurance-trained cyclists (VO2max > 50 ml/kg/min or 4.5 L/min), from James Madison 
University and the surrounding area performed all testing. Prior to any testing, subjects were 
required to read and sign informed consent forms, which provided details describing the study, 
the risks and benefits of the study, and confidentiality of the study. All procedures were approved 




Subjects were asked to complete five total trials, each separated by 5-10 days. 
Specifically, subjects completed one pre-testing trial, one familiarization trial, and three 
experimental trials. During the three experimental trials, subjects ingested a whey protein 
hydrolysate solution, L-alanine solution, or a flavored placebo. 
 
Preliminary Testing 
Subjects reported to the Human Performance Laboratory where their height (nearest 0.5 
cm) and weight (nearest 0.1 kg) was recorded. Their VO2max and associated power output (Wmax) 
was assessed using a graded exercise test on a Racermate Velotron (Seattle, WA) cycle 
ergometer. Subjects cycled at a self-selected workload estimated as “a comfortable, but not easy 
pace for a 1-hour ride.” The workload was be increased by 25 watts every 2 minutes until subjects 
voluntarily requested to stop due to fatigue or were unable to continue at a cadence >50 rpms. 
Metabolic measurements were assessed throughout each stage of the test using a Moxus Modular 
Metabolic System (Bastrop, TX). Heart rate was continually assessed using a Suunto heart rate 












Subjects performed the protocol that was used during the experimental trials while 
consuming water only (Figure 3.1). 
 
Experimental Trials 
Subjects completed three separate experimental trials on a Racermate Velotron (Seattle, 
WA) cycle ergometer. Each trial consisted of two exercise phases. The first phase consisted of 
120 minutes of steady-state cycling at 55% Wmax (determined during preliminary testing). The 
steady-state portion was immediately followed by a simulated 30-km time trial (TT; ~50 min.), as 
outlined in Figure 3.1.  
All trials were conducted at ambient room temperature. Subjects were asked to void their 
bladders prior to all trials. An oscillating fan was utilized on “high” speed setting and placed two 
meters from the handlebars for uniform cooling during trials. Subjects were encouraged to treat 
the TT portion of each trial as a competitive event and provide a maximal effort. Subjects 
received no feedback regarding performance during the TT except for distance completed and 
distance remaining. Researchers provided no verbal encouragement during the TT. 
 
Treatments 
As outlined above, subjects performed three experimental trials. During these trials, 
subjects consumed three different solutions. Subjects received 45 g/hr of whey protein 
hydrolysate (PRO; American Casein Company, Burlington, NJ), 15 g/hr of L-alanine (ALA; 
Ajinomoto North America, Fort Lee, NJ), or a non-caloric artificially sweetened placebo (PLA), 








electrolytes (Sodium and Potassium) and artificial vanilla flavoring (Baker’s Imitation Vanilla; 
McCormick & Company, Sparks, MD). Immediately prior to each trial, subjects received 250 ml 
of an experimental beverage. Thereafter, subjects received 250 ml every 15 minutes during the 
steady state portion of the trial. Another 250 ml was provided at three time points during the 30 
km TT (7.5, 15, and 22.5 km).  Treatment timing is outlined in Figure 3.1. 
 
Figure 3.1: Experimental Trial Protocol 
 
120 min Steady State (55% Wmax) 30-km TT 
 
 
Beverage   = 
Blood Draw  = 
 
Performance and Physiological Data 
Performance  
Exercise performance was measured using cycling time and mean power output (watts) 
for the pre-loaded simulated 30-km TT. Three subjects performed repeated pilot trials under 




Venous blood samples (3 ml) were collected from an antecubital vein prior to exercise 
and following 120 min of exercise. Blood was centrifuged and serum samples stored at -80°C 
until analyzed. Concentrations of serum IL-6 were analyzed with a standard enzyme-linked 









Metabolic measurements assessed using a Moxus Modular Metabolic System (Bastrop, 
TX) at the following time points: minutes 15, 35, 55, 75, 95, and 115 of the 120-min steady state 
phase, and at 20-km into the 30-km TT. At each of these points, 5 minutes of expired gas 
collection was performed and an average of the last three minutes were recorded. Dependent 
measurements obtained/derived from expired gases included oxygen uptake (VO2), ventilation 
rate (VE), and respiratory exchange ratio (RER).  
 
Blood Glucose and Lactic Acid 
Finger-stick blood samples (~0.5 ml) were obtained at the following time points: minutes 
20, 40, 60, 80, 100, and 120 of the 120-min steady state phase, and at 20-km into the 30-km TT. 
Glucose and lactate levels was determined immediately from whole blood using automated 
instrumentation (YSI 2300 STAT glucose/lactate analyzer).  
 
Heart Rate 
Heart rate was recorded at the time-points above (finger-stick time points) using a Suunto 
heart rate monitor.  In addition, average heart rate for the 30-km TT was recorded.  
 
Ratings of Perceived Exertion (RPE) 
Subjective ratings of exertion were obtained by having subjects point to a corresponding 
level of exertion (rated numerically from 6-20) on a Borg RPE scale.  RPE was obtained at the 
time-points indicated above (finger-stick time points).  
 
Gastrointestinal Distress Scale 
Subjects were asked to complete a questionnaire (verbally) at minutes 30, 60, 90, and 120 








questionnaire contained queries about the presence of GI symptoms at that moment and addressed 
the following complaints: stomach problems, GI cramping, bloated feeling, diarrhea, nausea, 
dizziness, headache, belching, vomiting, and urge to urinate or defecate. The items were scored 
on a 10-point scale (1 = not at all, 10 = very, very much). The severities of the GI symptoms were 
divided into two categories, severe and nonsevere symptoms. Symptoms were only registered as 
severe symptoms when a score of ≥5 out of 10 was reported. Scores of <5 were reported as 
nonsevere.  
 
Dietary and Exercise Controls 
Subjects were asked to: 1.  Maintain consistent dietary habits for 72 hours prior to each 
trial, 2.  Record food intake 24 hours prior to their first experimental trial, 3.  Replicate their exact 
food intake for the 24 hours preceding each subsequent experimental trial,  4.  Refrain from heavy 
and unaccustomed exercise for 48 hours prior to each experimental trial, 5.  Maintain consistent 
exercise habits between trials and record all physical activity performed during the 72 hours 
preceding each experimental trial, and 6.  Abstain from alcohol and caffeine for 24 hours and 12 
hours prior to the experimental trials, respectively. Subjects performed all trials in the fed state. 
Additionally, subjects consumed a liquid meal replacement (Ensure® Shakes; 20-25% of daily 
caloric intake) in the evening prior to each trial (7-9 hours prior). Two hours prior to all 
experimental trials, subjects consumed a standardized meal consisting of ~500 kcals. 
 
Statistical Analyses 
 Treatment effects on 30-km TT performance, VO2, VE, HR, RPE, blood glucose, and 
blood lactate were analyzed with a repeated-measures ANOVA, with treatment as the within 
subject factor. Pairwise comparisons were performed using paired t-tests with a Bonferroni 
correction. Friedman Tests were applied to the following variables that were not normally 








RPE (min 20).  The serum IL-6 response to exercise (pre vs. post- 120-min FI), for each 
treatment, was analyzed with Wilcoxen Signed Ranks tests. Significance was set at P < 0.05. All 
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Previous studies have reported that adding protein (PRO) to a carbohydrate (CHO) 
solution can enhance endurance performance. This ergogenic effect may be a function of 
additional calories from supplemental protein/amino acids, but this thesis has not been directly 
examined. Additionally, L-alanine (ALA) is readily oxidized when provided during exercise; the 
impact that this has on metabolism and prolonged endurance performance is unknown. The 
purpose of this investigation was to assess performance and various cardiovascular and metabolic 
outcomes during prolonged cycling, to independently gauge the efficacy of whey PRO 
hydrolysate and L-alanine (ALA) supplementation. Eight trained male and female cyclists (age: 




) performed 120 min of 
constant-load cycling (55% of peak power, 161.9±7.4 W) followed by a 30-km time trial (TT) 
under placebo (PLA), PRO, and ALA
 
conditions. TT performance was not different between 
treatments (PLA: 57.6±1.6 min, ALA: 58.8±1.5 min, PRO: 58.8±1.8 min). VE, VO2, heart rate, 
rating of perceived exertion, blood glucose, blood lactate, and gastrointestinal distress were also 
similar across experimental conditions. Conversely, serum interleukin-6 (IL-6) levels following 
120 min of cycling were elevated above rest with PLA (pre: 0.56±0.16, post: 3.14±0.84) and 
ALA (pre: 1.14±0.46, post: 2.62±0.71) (p<0.05), but not with PRO intake (pre: 0.81±0.25, post: 
1.55±0.32). The ingestion of PRO or ALA alone does not appear to enhance performance during 
prolonged cycling. Thus the ergogenic effects of CHO+PRO co-ingestion reported by others are 









The capacity for carbohydrate (CHO) intake to enhance endurance performance has been 
widely recognized since early work demonstrated that CHO provision preserves blood glucose 
levels, carbohydrate oxidation rates, and consequently improves performance (Coyle et al. 1983). 
The ergogenic potential of protein (PRO) has only recently been addressed. Initial studies 
indicated that adding small doses of PRO (~9-12 g·hr
-1
) to standard CHO treatments (30-60 g·hr
-
1
) enhanced performance in time-to-fatigue trials to a large extent (29-36%) (Ivy et al. 2003; 
Saunders et al. 2004). Subsequent research has been mixed, as PRO co-ingestion with CHO was 
beneficial in some studies (Ferguson-Stegall et al. 2010; Ghosh et al. 2010; Saunders et al. 2007; 
Saunders et al. 2009), but not others (Breen et al. 2010; Osterberg et al. 2008; Romano-Ely et al. 
2006; Valentine et al. 2008; van Essen and Gibala 2006). Importantly, recent meta-analyses have 
indicated a probable ergogenic benefit when PRO is provided with CHO (Stearns et al. 2010; 
Vandenbogaerde and Hopkins 2011). 
Although adding PRO to a CHO solution can benefit endurance performance under 
certain conditions, a major limitation of the current literature is the lack of a mechanistic 
explanation for how PRO may facilitate this response. The benefits of CHO+PRO are most 
prominent when tested against CHO-matched formulas (Ivy et al. 2003; Saunders et al. 2007; 
Saunders et al. 2009; Saunders et al. 2004), prompting speculation that the ergogenic effect of 
CHO+PRO may simply be a function of supplemental calories. This is a logical thesis but it 
awaits confirmation, as the effects of ingesting PRO calories in isolation have not been examined. 
Moreover, the potential interactive properties of CHO and PRO (Rowlands et al. 2012a; Wapnir 
et al. 1997) invites the possibility that PRO may influence performance only when in the presence 
of exogenous CHO. This study was therefore conceived to provide insight into a possible 
mechanism through which PRO alters endurance performance. Specifically, the current project 
was designed to evaluate whether or not a moderate dose (45 g·hr
-1
) of whey PRO hydrolysate 








Using this same experimental framework, a separate purpose of the study was to evaluate 
the ergogenic effect of ingesting L-alanine (ALA), an amino acid constituent of whey PRO (and 
many other PRO sources). ALA is the principle amino acid extracted by the liver for 
gluconeogenesis, and is oxidized/decarboxylated during endurance exercise (Felig et al. 1970; 
White and Brooks 1981). Exogenous ALA is readily oxidized (51 of 73 g ingested) during 
prolonged exercise (Korach-André et al. 2002). Further, when provided at ~25 g·hr
-1
, ALA is 
oxidized (0.35 g·min
-1
) at rates similar to CHO (0.43 g·min
-1
) (Korach-André et al. 2002; 
Peronnet et al. 1990). Thus it is theoretically possible for ALA to enhance endurance performance 
through mechanisms related to CHO metabolism (i.e. conserving liver and/or muscle glycogen). 
Although ALA supplementation does not appear to improve performance lasting ~60 min (Klein 
et al. 2009), the potential for the metabolic effect of ALA to enhance prolonged exercise 
performance has not been investigated.  
We were also interested in gaining insight into the impact that PRO and/or ALA intake 
may have on serum interleukin-6 (IL-6) levels. IL-6 is a myokine released from active skeletal 
muscle that is capable of impacting metabolism (Pedersen et al. 2007). For instance, IL-6 
enhances hepatic amino acid uptake and gluconeogenic gene expression (PEPCK), thereby 
promoting gluconeogenesis (Banzet et al. 2009; Fischer et al. 1996; Watkins et al. 1994). The 
magnitude of the IL-6 response to exercise is partially mediated by metabolic conditions; muscle 
glycogen depletion potentiates the plasma IL-6 response to exercise (Keller et al. 2001; 
MacDonald et al. 2003; Steensberg et al. 2001), whereas CHO supplementation attenuates plasma 
IL-6 levels (Febbraio et al. 2003; Nehlsen-Cannarella and Fagoaga 1997). Therefore, IL-6 levels 
were measured to provide general information about how PRO and ALA may influence the 











MATERIALS AND METHODS 
Subjects 




) from James Madison 
University and the Harrisonburg area volunteered to participate in this study. Two subjects 
withdrew prior to completion because of circumstances unrelated to the study, resulting in 
complete data from eight subjects (four males and four females). Subjects were provided written 
and oral information about experimental procedures and potential risks prior to giving informed 
consent. All procedures were approved by the James Madison University Institutional Review 
Board prior to any testing. Subject characteristics are displayed in Table 1. 
 
Cardiorespiratory Fitness 
Subjects performed an incremental exercise test to exhaustion on a bicycle ergometer 
(Velotron, Racermate, Inc., Seattle, WA, USA) to determine VO2max. Subjects began the test at a 
self-selected workload estimated as “a comfortable, but not easy pace for a 60-min ride.” Power 
was then increased by 25 W every two-min until the subject reached volitional exhaustion. 
Metabolic measurements were assessed throughout each stage of the test using a Moxus Modular 
Metabolic System (AEI Technologies, Pittsburgh, PA, USA). VO2max was determined by the 
highest 30-sec mean oxygen uptake value. Peak power at VO2max (Wmax) was defined by the 
power corresponding to the final successful stage, and was used to prescribe workload for the 
120-min constant-load segment of subsequent trials. 
 
Exercise Trials 
Subjects completed four trials (one familiarization trial followed by three experimental 
trials) on the aforementioned cycle ergometer. Trials consisted of 120-min of constant-load 
cycling at 55% Wmax (162 ± 21 W) followed by a simulated 30-km TT, each separated by 5-14 








blood samples were obtained, and subjects received only water while cycling. Subjects were 
asked to void their bladder prior to all trials. A pedestal fan was placed ~2 m from the handlebars 
and utilized on high speed setting for uniform cooling during each trial. Subjects were 
encouraged to treat the TT portion of each trial as a competitive event and provide a maximal 
effort. Subjects did not receive performance feedback during the TT other than elapsed- and 
remaining distance, and no verbal encouragement was provided during the TT.  
 
Treatments 
We implemented a randomly-counterbalanced, double-blind, placebo-controlled study 
that was designed to compare the effects of three separate treatment conditions on performance, 
cardiovascular and metabolic physiology, and serum IL-6. The treatments were: 1) PRO: 45 g·L
-1
 
of whey protein hydrolysate (American Casein Company, Burlington, NJ, USA), 2) ALA: 15 g·L
-
1
 of L-alanine (Ajinomoto North America, Fort Lee, NJ, USA), and 3) PLA: non-caloric 
artificially sweetened placebo (Splenda, Fort Washington, PA, USA). Each solution also 
contained 470 mg·L
-1 
sodium chloride (Morton Salt, Chicago, IL, USA), 200 mg·L
-1 
potassium 
chloride (NOW Foods, Bloomingdale, IL, USA), and 4.1 g·L
-1
 artificial vanilla flavoring (Baker’s 
Imitation Vanilla; McCormick & Company, Sparks, MD, USA). Immediately prior to each trial, 
subjects received 250 ml of treatment beverage. Thereafter, subjects received a 250 ml feeding 
every 15 minutes during the constant-load portion of the trial, and at three points during the TT 
(7.5, 15, and 22.5 km). Although optimal rates of exogenous PRO provision are unknown, 
previous work has examined PRO co-ingestion at rates ranging from ~5-20 g·hr
-1
, rates that are 
particularly low when compared to those recommended for CHO (30-60 g·hr
-1
). This invites the 
possibility that higher doses of PRO are required to optimize the ergogenic effect of PRO. 
Therefore, a PRO ingestion rate of 45 g·hr
-1
 was selected as it falls within the range of 
recommended carbohydrate delivery rates (30-60 g·hr
-1
) during prolonged exercise (Coyle 2004). 










 (Klein et al. 2009). However, ALA was delivered at 15 g·hr
-1
 in the present study, because 
higher doses were not well-tolerated during pilot testing. 
 
30-km TT Performance  
Finishing time and mean power output (watts) during the 30-km TT were used as 
performance criteria. We have previously assessed the reproducibility of cycling time/power 
measurements using identical equipment in our laboratory.  Using a similar performance trial (20-
km of cycling over a simulated hilly course), the coefficient of variation (CV) between repeated 
trials (under placebo conditions, following a familiarization trial) was 1.4% for time, and 2.6% 
for power output (Goh et al. 2012). Further, we obtained repeatability data for this protocol from 




Oxygen uptake (VO2), expired ventilation (VE) and respiratory exchange ratio (RER) 
were assessed using a Moxus Modular Metabolic System (AEI Technologies, Pittsburgh, PA, 
USA) at the following time points: 15-20 min and 115-120 min of constant-load cycling, and at 
20-km of the TT. These time points were selected to correspond with early exercise, late exercise, 
and the TT. Aggregates of the final three minutes of each phase were recorded. 
 
Heart Rate and Rating of Perceived Exertion 
HR (Suunto, Vaanta, Finland) and rating of perceived exertion (RPE; 6-20 Borg Scale) 











Blood Glucose and Lactate 
Finger-stick blood samples (~0.5 ml) were obtained at the following time points: 20- and 
120 min of constant-load cycling, and at 20-km of the TT. Glucose and lactate levels were 
determined immediately from whole blood using automated instrumentation (YSI 2300 STAT 
glucose/lactate analyzer, Yellow Springs, OH, USA).  
 
Gastrointestinal Distress Scale 
Subjects verbally indicated their perceived level of gastrointestinal (GI) distress at 30- 
and 120 min of constant-load cycling and at 20- and 30-km of the TT. Utilizing a 10-point scale 
(1 = not at all, 10 = very, very much), subjects rated the following symptoms: stomach problems, 
GI cramping, bloated feeling, diarrhea, nausea, dizziness, headache, belching, vomiting, and urge 
to urinate or defecate (Jentjens et al. 2002).  
 
Serum Interleukin-6 
Venous blood samples (~3 ml) were collected from an antecubital vein prior to exercise 
and following 120 min of constant-load exercise (~3 min post-exercise). All samples were 
obtained under standardized postural conditions (reclined in a chair). Blood was allowed to clot 
for 30 min prior to being centrifuged at 3 000 rpm for 10 min. Serum samples were stored at -
80°C until analyzed. Quantikine high sensitivity enzyme-linked immunosorbent assay kits (R&D 
Systems, Minneapolis, MN) were used to measure IL-6 in serum, according to manufacturer’s 
instructions. 
 
Dietary and Exercise Controls 
Subjects were instructed to: 1) Practice consistent dietary habits for 72 hours prior to each 
trial, 2)  Record food intake 24 hours prior to their first experimental trial and replicate their exact 








and/or unaccustomed exercise for 48 hours prior to each experimental trial, 4)  Maintain 
consistent exercise habits between trials and record all physical activity performed during the 72 
hours preceding each experimental trial, and 5)  Abstain from alcohol and caffeine for 24 hours 
and 12 hours prior to the experimental trials, respectively. Subjects performed all trials in the fed 
state. Specifically, subjects consumed 20-25% of their estimated daily caloric expenditure 
(Harris-Benedict equation) in the form of a liquid meal replacement (Ensure® Shakes, Abbott 
Laboratories, Abbott Park, IL, USA) in the evening prior to each trial (immediately prior to 
sleep). Two hours prior to all exercise trials, subjects consumed a standardized meal consisting of 
~500 kcals (cereal with milk, orange juice, and strawberry yogurt). 
 
Statistical Analyses 
Data that displayed normality (RER, HR, and lactate) were analyzed with 2 x 3 repeated-
measures ANOVAs, with time (early and late constant-load exercise) and treatment (PLA, ALA, 
and PRO) as within-subject factors. The effects of treatment on 30-km TT performance and RER, 
HR, and lactate during the TT were analyzed with repeated-measures ANOVAs (treatment as 
within-subject factor). Wilcoxen Signed Ranks tests were applied to examine the effects of 
constant-load exercise (treatments were aggregated within each time point) and Friedman Tests 
were performed to determine the effects of treatment (within each time point) on the following 
variables that were not normally distributed: GI distress symptoms, blood glucose, VE, VO2, and 
RPE.  The serum IL-6 response to exercise (pre vs. post- 120-min constant-load), for each 
treatment, was analyzed with Wilcoxen Signed Ranks tests. Significance was set at P < 0.05. All 













30-km Time Trial Performance 
Time trial performance was not influenced by treatment (Figure 1). Performance times 
were:  PLA, 57.6 ± 1.6 min; ALA, 58.8 ± 1.5 min; PRO, 58.8 ± 1.7 min. Likewise, average power 
output during the TT was similar across treatments: PLA, 175 ± 14 W; ALA, 166 ± 11 W; and 
PRO, 167 ± 13 W.  
 
VO2, VE, RER, HR, and RPE  
VE, RER, HR, and RPE during exercise are displayed in Table 2. No treatment 
differences were observed for any variable during the TT. Likewise, there was no treatment effect 
for RER or HR during constant-load cycling, although there was a main time effect. Specifically, 
RER was diminished and HR elevated at min 120 compared to min 20 of constant-load cycling 
(p<0.05). Similarly, VE, VO2, and RPE were not influenced by treatment during constant-load 
cycling, but all three variables were elevated at min 120 compared to min 20 of constant-load 
cycling (p<0.05).  
 
Blood Glucose and Lactate 
Blood glucose and lactate data are displayed in Table 3. No treatment differences were 
observed for either variable during the TT. Likewise, there was no time or treatment effect for 
blood lactate during constant-load cycling. Similarly, blood glucose was not influenced by 
treatment or time during constant-load cycling.  
 
GI Distress Symptoms 
GI distress symptoms were not different between treatments at any time point. With the 
exception of the symptom urge to urinate, all subjective GI ratings were non-serious (≤ 4) during 








serious nausea symptoms at the end of the 30-km TT (0, 1, 3 instances in PLA, ALA, and PRO, 
respectively), and two of these subjects also reported serious symptoms at 20-km (2 instances in 
PRO). Individual ratings of nausea during the TT are presented in Table 4. Average ratings of 
nausea symptoms at 30-km were: PLA, 1.25 ± 0.25; ALA, 2.00 ± 0.68; PRO, 3.13 ± 0.83. 
Finally, with the exception of an increase in the ‘urge to urinate’ (p<0.05), GI distress symptoms 
were similar between min 20 and min 120 of constant-load cycling.  
 
Serum Interluekin-6 
Post-exercise IL-6 levels were elevated above rest with PLA (rest: 0.56 ± 0.16 pg·ml
-1
, 
post-exercise: 3.14 ± 0.84 pg·ml
-1
) and ALA (rest: 1.14 ± 0.46, post-exercise: 2.62 ± 0.71) (P < 
0.05), but not PRO (rest: 0.81 ± 0.25, post-exercise: 1.55 ± 0.32). Resting and post-exercise 























 We assessed 30-km cycling TT performance and various cardiovascular and metabolic 
outcomes during prolonged cycling to gauge the efficacy of PRO and ALA supplementation. 
Most notably, 30-km TT performance was not affected by either PRO or ALA intake. This was 
affirmed by the global physiological response, as cardiovascular and metabolic parameters were 
also similar across experimental conditions. The only notable disparity among treatments was that 
IL-6 levels increased with both PLA and ALA, but not PRO. This is the first evidence that PRO 
feedings can attenuate the IL-6 response to prolonged exercise, albeit not in a manner that altered 
substrate utilization, blood glucose levels, or performance.  
Previous studies have found the functional worth of CHO+PRO supplementation during 
endurance exercise to be most obvious when compared to CHO-matched formulas (Ivy et al. 
2003; Saunders et al. 2007; Saunders et al. 2009; Saunders et al. 2004), suggesting that the gains 
in performance are simply a function of additional energy (calories). We tested this inference by 
evaluating the isolated effects of PRO on performance (i.e. in the absence of CHO). In an attempt 
to maximize the potential ergogenic effect, a markedly higher dose of PRO (45 g·hr
-1
) was 
provided relative to previous investigations (6-20 g·hr
-1
; Breen et al. 2010; Ivy et al. 2003; 
Martinez-Lagunas et al. 2010; Osterberg et al. 2008; Romano-Ely et al. 2006; Saunders et al. 
2009; Saunders et al. 2004; Valentine et al. 2008; van Essen and Gibala 2006). One inherent risk 
of higher dosing is impaired gastric emptying (Hunt and Stubbs 1975) and consequential 
gastrointestinal (GI) distress (Rehrer et al. 1989), which could potentially mask an otherwise 
beneficial effect on performance (Rowlands et al. 2012b). While GI symptoms were not 
statistically different between treatments in the current study, three of the eight subjects 
experienced severe nausea (≥ 5 on 10 point scale) immediately following the 30-km TT under 
PRO conditions. However, among the five subjects that did not experience GI distress with PRO 
intake, only one completed the TT faster in the PLA condition. Thus, it is likely that the current 








These findings indicate that previously documented improvements in performance cannot 
be explained by additional PRO calories per se, but rather may be related to ‘non-caloric’ 
mechanisms of PRO. For example, PRO consumption may increase intestinal absorption rates of 
sodium, water, and glucose. Neutral amino acids are co-transported with sodium across the 
intestines via glucose independent transporters (Coëffier et al. 2005). This additional sodium 
absorption across the gut may facilitate better transport of fluid and CHO via solvent drag 
(Rowlands et al. 2012a; Van Loon et al. 1996; Wapnir et al. 1988; Wapnir et al. 1997). Therefore, 
the potential exists for PRO co-ingestion to support the effects of CHO-based beverages on 
performance. More specific to the current investigation, this dynamic is heavily influenced by 
fluid osmolarity such that high amino acid concentrations cease to aid sodium and fluid 
absorption (Wapnir and Lifshitz 1985; Wapnir et al. 1988; Wapnir et al. 1997). Considering the 
relatively high PRO dose used in the current study, it is likely that fluid and sodium absorption 
were not altered, which is consistent with the lack of performance and physiological differences 
between treatments. 
In the current study serum IL-6 levels were elevated following 120 minutes of constant-
load cycling with PLA and ALA treatments, but were unchanged with PRO. This is the first 
evidence that IL-6 levels are attenuated by PRO intake during prolonged exercise. Muscle 
glycogen depletion has been shown to potentiate the release of IL-6 from the muscle during 
exercise (Keller et al. 2001; MacDonald et al. 2003; Steensberg et al. 2001). Conversely, CHO 
ingestion diminishes the release of IL-6 from the muscle during prolonged exercise, likely due to 
the preservation of endogenous CHO stores (Febbraio et al. 2003; Nehlsen-Cannarella and 
Fagoaga 1997; Nieman et al. 1998; Starkie et al. 2001). In view of these results, it is tempting to 
speculate that PRO increased muscle energy provision and attenuated endogenous CHO 
depletion. However, endogenous CHO preservation typically results in higher levels of CHO 
oxidation (and RER) late in exercise, which can benefit TT performance (Bergström and Hultman 








influence either of these variables (RER or performance), it is unlikely that endogenous CHO 
utilization was attenuated.  
Another possible explanation for the attenuation of IL-6 is related to muscle damage. The 
IL-6 induction with exercise appears to be partially evoked by muscle damage due to its role as 
an inflammatory cytokine (Bruunsgaard et al. 1997), although it appears to play a secondary role 
to energetics (Croisier et al. 1999; Pedersen 2012; Toft et al. 2002). The relatively subtle rise in 
serum IL-6 levels with the PLA and ALA treatments (2.58 and 1.49 pg·ml
-1
, respectively) was of 
a magnitude that could be credited to muscle damage, rather than a response to limited energy 
availability (Toft et al. 2002). Further, PRO co-ingestion has commonly attenuated creatine 
kinase and myoglobin levels, indirect markers of muscle damage, following prolonged exercise 
(Thomson et al. 2011; Valentine et al. 2008). Therefore, it is possible that an attenuation of 
muscle damage generated by PRO intake inhibited the IL-6 response to exercise. 
Similar to PRO, ALA supplementation failed to improve TT performance. This extends 
previous work demonstrating that performance in a relatively short duration time trial (~60 min) 
was unaffected by ALA provision (Klein et al. 2009). Exogenous ALA is oxidized nearly as 
efficiently as CHO during exercise when ingested at 25 g·hr
-1
 (Korach-André et al. 2002; 
Peronnet et al. 1990), making ALA an ideal model to determine whether or not nitrogenous 
sources are capable of affecting performance through the provision of supplemental calories. 
However, it appears that any ALA oxidation that occurred in the current study was insufficient to 
impact prolonged exercise performance. It remains possible that higher doses of ALA are 
required to exhibit a metabolic effect. However, larger ALA doses elicited severe GI discomfort 
during pilot testing, as well as a clear ergolytic effect. Therefore, ALA rates were reduced to 15 
g·hr
-1
 to alleviate these symptoms. Nonetheless, the lack of a performance effect likely was not 
the result of inadequate energy provision per se, as CHO supplementation has been shown to 
improve performance with ingestion rates of 15 g·hr
-1








provides further evidence that nitrogenous protein sources do not impart an ergogenic effect 
through caloric means.  
 Neither PRO nor ALA affected VO2, RER, HR, RPE, blood glucose, or blood lactate at 
any time point. The lack of a physiological response to PRO intake aligns with the preponderance 
of relevant work examining CHO+PRO ingestion (Ivy et al. 2003; Saunders et al. 2007; Saunders 
et al. 2004; Valentine et al. 2008). However, there is recent evidence that the presence of PRO 
(with CHO) can favorably impact HR and/or RPE during exercise (Hall et al. 2013; Martinez-
Lagunas et al. 2010; McCleave et al. 2011). As stated previously, low concentrations of amino 
acids are capable of augmenting intestinal absorption of sodium and fluid (Van Loon et al. 1996; 
Wapnir et al. 1988; Wapnir et al. 1997). This implies that PRO and/or ALA inclusion may better 
preserve blood volume and stroke volume during prolonged exercise, which would subsequently 
maintain HR late in exercise (Ekelund 1967). Perceived exertion during endurance activity is 
commonly linked to HR (Borg and Linderholm 1967) and can potentially explain lower RPE with 
CHO+PRO in these past studies (Hall et al. 2013; Martinez-Lagunas et al. 2010). Our data 
suggests that PRO/ALA alone do not influence these variables. However, as previously noted, the 
PRO intake rate in this study may have been too high to generate increased fluid absorption rates 
(Wapnir et al. 1988; Wapnir et al. 1997), negating this potential mechanism. No studies are 
available to either confirm or refute the conclusion that ALA consumption does not impact these 
cardiovascular and metabolic variables. If ALA had provided a critical amount of exogenous 
energy in this study, akin to CHO intake, RER and blood glucose would have likely been elevated 
compared to PLA (Coyle et al. 1986). However, this was not observed, agreeing with the lack of 
performance improvement from the ALA treatment. 
 The present study demonstrates that prolonged TT cycling performance and various 
cardiovascular and metabolic parameters are not impacted by either 45 g·hr
-1
 of whey PRO 
hydrolysate or 15 g·hr
-1
 of ALA. Although ALA can be efficiently oxidized during exercise, ALA 








may be required to elicit meaningful metabolic effects but do not appear to be well-tolerated by 
the GI system. Also, the similar performance times between PRO and PLA suggest that the 
ergogenic effects of CHO+PRO co-ingestion reported by others are not the result of additional 
PRO calories per se. Rather, it seems that the mechanism through which the inclusion of PRO 
enhances performance requires the interaction of the two macronutrients (i.e. exogenous CHO 






Table 4.1: Subject Characteristics 




 Wmax, Watts  
8 22.3 ± 2.0 173.1 ± 2.6 70.0 ± 2.8 59.4 ± 1.7 294 ± 14 











Table 4.2: VO2, VE, RER, HR, and RPE at 20 and 120 min of constant-load cycling (55% Wmax), 
and at 20-km during the time trial 
 20 min 120 min 20-km 
VO2 (L·min
-1
)    
      PLA 2.55 ± 0.10 2.71 ± 0.11 2.83 ± 0.18 
      ALA 2.49 ± 0.11 2.68 ± 0.10 2.80 ± 0.18 
      PRO 2.48 ± 0.09 2.74 ± 0.10 2.78 ± 0.17 
VE (L·min
-1
)    
      PLA 59.6 ± 2.0 63.2 ± 2.2 72.0 ± 6.6 
      ALA 59.4 ± 2.4 63.2 ± 2.4 70.0 ± 5.9 
      PRO 58.8 ± 2.6 64.4 ± 2.9 72.4 ± 7.4 
RER    
      PLA 0.89 ± 0.01 0.83 ± 0.01 0.82 ± 0.01 
      ALA 0.90 ± 0.02 0.84 ± 0.01 0.84 ± 0.01 
      PRO 0.90 ± 0.01 0.84 ± 0.01 0.83 ± 0.01 
HR (b·min
-1
)    
      PLA 137 ± 5 144 ± 5 153 ± 6 
      ALA 133 ± 3 141 ± 2 150 ± 4 
      PRO 140 ± 5 146 ± 5 152 ± 5 
RPE    
      PLA 12.4 ± 0.3 13.4 ± 0.5 15.8 ± 0.6 
      ALA 12.1 ± 0.2 13.3 ± 0.5 16.0 ± 0.6 
      PRO 11.9 ± 0.2 13.1 ± 0.5 15.8 ± 0.3 
Note: Values are expressed as means ± SE. VO2, oxygen consumption; VE, pulmonary 
ventilation; RER, respiratory exchange ratio; HR, heart rate; RPE, rating of perceived exertion; 
PLA, placebo; ALA, L-alanine; PRO, whey protein hydrolysate.  
 
All variables (VO2, VE, RER, HR, and RPE) were different (p<0.05) at min 120 compared 








Table 4.3: Blood glucose and lactate at 20 and 120 min of constant-load cycling (55% Wmax), and 
at 20-km during the time trial 
 
20 min 120 min 20-km 
BG (mg·dL
-1
)    
      PLA 73.7 ± 2.4 75.7 ± 2.3 72.9 ± 2.8 
      ALA 74.4 ± 3.2 72.6 ± 1.4 69.5 ± 2.0 




   
     PLA 1.1 ± 0.1 1.0 ± 0.1 1.6 ± 0.4 
     ALA 1.2 ± 0.1 1.3 ± 0.1 1.7 ± 0.2 
     PRO 0.9 ± 0.2 0.9 ± 0.1 1.3 ± 0.3 
Note: Values are expressed as means ± SE. BG, blood glucose; BLa, blood lactate; PLA, 























Table 4.4: Individual ratings of nausea at 20 and 30-km of time trial 
  20-km    30-km  
Subject PLA ALA PRO  PLA ALA PRO 
A 1 1 1  1 1 1 
B 1 1 1  1 1 1 
C 1 2 1  1 1 1 
D 1 1 5  3 4 6 
E 1 1 1  1 6 4 
F 1 1 1  1 1 1 
G 1 1 5  1 1 6 
H 1 1 1  1 1 5 
































Figure 4.2: Concentrations of IL-6 in arterial serum before and following 120 minutes of constant-load cycling with PLA, ALA, and PRO 
































Subjects Wanted for Cycling Study 
 
 
The Human Performance Laboratory at JMU will be conducting a study 
examining the effects of ingesting different beverages on cycling 
performance.   
 
 
Who Are We Looking For?  
 
 18-45 years old 
 
 Experienced cyclists 
(performing cycling exercise 
on a regular basis) 
 
 
What Will You Be Asked to Do? 
 
 Complete preliminary fitness testing/screening 
 
 Participate in four exercise protocols, each of which will consist of 3 
hrs of cycling on a computerized bicycle ergometer.  Beverages will 
be provided during each session 
 
 Receive laboratory assessments (including blood sampling) during 
each session 
 




What are the benefits of participation? 
 
 Free evaluation of aerobic capacity (VO2peak) and physiological data 
from a race simulation  
 
 $75 for study completion 
 
For more information, please contact Dr. Nick Luden at 
ludennd@jmu.edu and (540) 568-4069, or Adam Schroer at 
schroeab@dukes.jmu.edu and (812) 239-4356. 








James Madison University 





You are being asked to volunteer for a research project conducted by Dr. Nick Luden, 
Dr. Mike Saunders, Adam Schroer, and Dan Baur from James Madison University titled 
“Effect of Both Protein and Alanine Consumption on Performance and the Plasma 
Interleukin-6 Response during Prolonged Cycling”.  
 
The primary goal of this study is to determine the effect of sports beverages with 
differing amounts of nutrients (carbohydrate, fat, and protein) on cycling performance 





You will be asked to report to James Madison University’s Human Performance 
Laboratory (Godwin 209) on five occasions.  Specifically, you will be asked to participate 
in one preliminary trial, one familiarization trial, and three experimental exercise trials, 
each separated by 5 to 10 days.  The preliminary trial will require approximately 45 
minutes, whereas the familiarization trial and each experimental exercise trial will require 
approximately 3 hrs each, for a total time commitment of 12 hrs 45 min. Detailed 
information for each of these trials is provided below: 
 
Preliminary Trial – Visit 1 – 45 minutes 
 
Prior to any data collection, you will be asked to complete health history and screening 
questionnaires to ensure that you meet the study criteria and that you do not have any 
risk factors that would prevent you from performing heavy exercise. In the process of 
completing these forms, you will be asked to share information regarding your general 
health and lifestyle with the researchers. If you meet the criteria for the study, the 
researchers will measure your height and body weight and you will then be asked to 
perform a cardiovascular fitness test on a bicycle ergometer to determine your peak 
oxygen consumption (VO2peak). At the beginning of the test, you will be asked to ride the 
stationary bicycle ergometer at an initial workload that is ‘fairly easy’. The workload will 
be increased every two minutes during the test. You will be encouraged to continue to 
cycle until you request to stop due to fatigue or are unable to continue at a cadence of 
>50 revolutions per minute.  
 
Familiarization Trial and Experimental Exercise Trials – Visits 2, 3, 4, and 5 – 3 hrs each 
 
You will be asked to complete each trial on a stationary bicycle ergometer.  Each trial will 
consist of two distinct exercise phases. Specifically, each trial will include an initial 
steady-state segment of 120 min at 55% Wmax (‘moderate intensity’). The steady-state 
ride will be immediately followed by a simulated 30-km time trial (~60 minutes). Total 
exercise time will be approximately 3 hrs. During each of these five trials, you will 
receive water or a protein sports beverage at various time-points.  Each of the trials will 







be separated by a minimum of 5-10 days. A different beverage will be provided during 
each trial.  You will consume the beverages according to the following schedule: 
- 250 ml of the assigned beverage will be provided in a bottle immediately prior 
to exercise. 
- 250 ml will be provided every 15 min during the steady state portion of the 
trial.  
- 250 ml will also be provided at 7.5, 15, and 22.5 km of the time trial.  
You will be instructed to consume the beverages within 5 minutes during exercise.  The 
beverages will have slightly different ingredients during each trial (see Study Treatments 
below). 
 
You will be asked to void your bladder prior to each trial.  You will also be encouraged to 
treat all time trials as a competitive event, and provide a maximal effort. You will receive 
no feedback regarding performance during the time-trials, except for the distance 
completed and distance remaining in the trial.  The researchers will not provide any 
verbal encouragement.   
 
You will be asked to complete the following procedures during each protocol: 
 
Exercise Performance 
Performance will be measured by your finishing times (and average power output) in the 
30-km time trial.  Again, these are to be approached as competitions. 
 
Metabolic Measurements   
Metabolic measurements such as oxygen uptake, ventilation, etc. will be measured with 
a metabolic cart at the following time points: minutes 15, 35, 55, 75, 95, and 115 of the 
120-min steady state phase, and at 20-km into the 30-km time trial. At each of these 
points, 5 minutes of expired gas will be collected.  To do this, you will be asked to 
breathe through a mouthpiece/breathing apparatus that collected your expired breath. 
This apparatus will NOT be worn during exercise other than at the indicated time points.  
 
Blood Glucose and Lactic Acid 
A total of 8 finger-stick blood samples (~0.5 ml) will be obtained at the following time 
points: minutes 20, 40, 60, 80, 100, and 120 of the 120-min steady state phase, and at 
20-km into the 30-km time trial. Each of these samples will be obtained by puncturing 
your fingertip with a small lancet.  A very small amount of blood (~2 drops) will be 
collected at each time point.   
 
Heart Rate   
You will be asked to wear a heart rate monitor around your chest. Heart rate will be 
monitored throughout each exercise session.   
 
Ratings of Perceived Exertion (RPE) 
You will be asked to provide subjective ratings of your exertion level.  You will do this by 
pointing to a corresponding level of exertion (rated numerically from 6-20) on a Borg 
RPE scale.  
 
Gastrointestinal Distress Scale 
You will be asked to complete a questionnaire (verbally) at several points throughout the 
exercise session. The questionnaire contains questions regarding the presence of GI 
problems at that moment and addresses the following complaints: stomach problems, GI 







cramping, bloated feeling, diarrhea, nausea, dizziness, headache, belching, vomiting, 
and urge to urinate or defecate.  
 
Plasma IL-6 
Blood samples (~3 ml) will be obtained via venipuncture from the antecubital vein prior to 
exercise and after 120 min of exercise. Blood samples will be collected while you are in 
the seated position. 
 
Dietary and Exercise Controls   
 
You will be asked to complete a diet record for the 24-hr preceding each treatment trial.  
You will also be asked to bring your initial diet record with you to the laboratory on the 
morning of your first experimental trial (diet record from previous day).  You will be 
provided with a copy of this dietary log, which is to be used as a template when 
replicating your dietary habits for the 24-hrs leading up to each of the following trials. 
You are also asked to refrain from heavy exercise for 48-hours prior to each trial.  You 
will be asked to keep a record all physical activity performed during the 72-hr preceding 
each treatment trial and to maintain consistent exercise habits between each of these 
trials.  You are to consume your final ‘self-selected’ meal no less than 12 hours prior to 
the start of the exercise trials (i.e. dinner on the evening prior to testing).  Approximately 
7-9 hrs prior to each trial (the night before), you will consume a liquid meal replacement 
(Ensure® Shakes) at an amount corresponding to 20-25% of daily caloric intake. 2 hrs 
prior to all experimental trials, you will consume a standardized breakfast consisting of 
~500 kcals (provided by the researchers). Finally, you will be asked to abstain from 





You are expected to be honest about disclosing all known risk factors to the researchers. 
According to the American College of Sports Medicine, the risks associated with 
maximal exercise/testing for healthy individuals are very minimal.  To be included in this 
study, you will need to meet the criteria for “low risk”. In the unlikely event of cardiac or 
other complications during exercise, an emergency plan is in place.  This includes 
immediate access to a phone to call emergency personnel.  In addition, at least one 
investigator present at all testing sessions will be CPR certified.   
 
The exercise protocol may result in minor-moderate levels of muscle soreness and 
fatigue for 1-2 days following each exercise session.  However, the level of muscle 
soreness is expected to be lower than levels normally experienced when you perform 
other ‘normal’ activities that are not part of your regular exercise routine (i.e. if a cyclist 
played a game of basketball with friends for 2 hours).  
 
The consumption of relatively large amounts of sports drinks can increase the risk of 
digestive issues; include symptoms such as nausea, stomach cramping, bloated feeling, 
vomiting, dizziness, and diarrhea. These symptoms may cause mild discomfort for a 
short-term period, but are not life-threatening. Digestive symptoms will be monitored 
throughout testing, and tests will be terminated if your symptoms become severe enough 
to require you to cease exercise.  
The risks of venipuncture and finger stick blood sampling include possible mild bruising, 
and the risk of transfer of blood-borne pathogens, as well as possible risks of infection or 







skin irritation.  This risk is considered to be minimal, and all safety precautions for 
handing blood samples will be followed according to OSHA protocols. The investigators 





The benefits associated with this project include a free VO2peak assessment, and a $75 
payment for study completion.  In the case of withdrawal, payments will be pro-rated 
such that you will receive $25 for the completion of each experimental trial (steady-state 
+ TT). Participation in this novel research project will also contribute to our 





All data and results will be kept confidential.  You will be assigned an identification code.  
At no time will your name be identified with individual data.  The researchers retain the 
right to use and publish non-identifiable data.  All data will be kept secured in a locked 
cabinet.  Upon completion of the study, all information that matches up individual 
respondents with their answers will be destroyed.  Final aggregate results will be made 
available to you upon request.  
 
 
Participation & Withdrawal  
 
Your participation is entirely voluntary.  You are free to choose not to participate.  Should 




Questions about the Study 
 
If you have questions or concerns during the time of your participation in this study, or 
after its completion or you would like to receive a copy of the final aggregate results of 
this study, please contact: 
Adam Schroer     Dr. Nick Luden 
Kinesiology     Kinesiology 
James Madison University   James Madison University 




Questions about Your Rights as a Research Subject  
 
Dr. David Cockley  
Chair, Institutional Review Board  
James Madison University  
(540) 568-2834  
cocklede@jmu.edu  
 








Giving of Consent 
 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given satisfactory 
answers to my questions.  The investigator provided me with a copy of this form.  I 
certify that I am at least 18 years of age. 
 
______________________________________     
Name of Participant (Printed) 
 
______________________________________    ______________ 
Name of Participant (Signed)                                    Date 
______________________________________    ______________ 
Name of Researcher (Signed)                                   Date 








Age:    
 
Height:    Weight:    
 
 
Average Exercise Habits over the Past 2 Months: 
 
Avg. # days of exercise per week:       
 
Avg. # of days of aerobic exercise per week:     
 
Avg. # of days of cycling per week:      
 
 
Do you have a muscle or joint injury/condition that precludes the completion of 


































AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire  
Assess your health status by marking all true statements 
 
History 
You have had: 
   a heart attack 
   heart surgery 
   cardiac catheterization 
   coronary angioplasty (PTCA) 
   pacemaker/implantable cardiac 
   defibrillator/rhythm disturbance 
   heart valve disease 
   heart failure 
   heart transplantation 
   congenital heart disease 
 
Symptoms 
   You experience chest discomfort with exertion 
   You experience unreasonable breathlessness 
   You experience dizziness, fainting, or blackouts 
   You take heart medications 
 
Other Health Issues 
   You have diabetes 
   You have asthma or other lung disease 
   You have burning or cramping sensation in your lower  
   legs when walking short distances 
   You have musculoskeletal problems that limit your  
   physical activity 
   You have concerns about the safety of exercise 




Cardiovascular risk factors 
   You are a man older than 45 years 
   You are a woman older than 55 years, have had a  
   hysterectomy, or are postmenopausal 
   You smoke, or quit smoking within the previous 6 months 
   Your blood pressure is > 140/90 mmHg 
   You do not know your blood pressure 
   You take blood pressure medication 
   Your blood cholesterol level is > 200 mg/dl 
   You do not know your cholesterol level 
   You have a close blood relative who had a heart attack or 
   heart surgery before age 55 (father or brother) or age 65 
       (mother or sister) 
   You are physically inactive (i.e. you get < 30 minutes of  
   physical activity on at least 3 days of the week) 
   You are > 20 pounds overweight 
 
 
   None of the above 
If you marked any of these statements 
in this section, consult your physician 
or other appropriate health care 
provider before engaging in exercise.  
You may need to use a facility with a 
medically qualified staff. 
If you marked two or more 
of the statements in this 
section, you should consult 
your physician or other 
appropriate health care 
provider before engaging in 
exercise.  You might benefit 
from using a facility with a 
professionally qualified 
exercise staff to guide your 
exercise program. 
You should be able to exercise safely without 
consulting your physician or other appropriate health 
care provider in a self-guided program or almost any 
facility that meets your exercise program needs. 
If you marked that you have 
diabetes but did not mark any 
other statements, physician’s 
approval will be necessary 
before engaging in the study. 
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